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Summary  
 
Natural products play an important role as source of inspiration for drug discovery 
and development and as tools for basic research. Isolated natural products that had 
shown diverse biological activity in previously published tests were analysed for their 
direct effect on molecular signalling processes, militarinone A from the 
entomogenous fungus Paecilomyces militaris and indolinone from Isatis tinctoria. 
The fungal alkaloid militarinone A was originally identified in a screening for 
neurotrophic substances, where it induced neuronal outgrowth in PC12 cells. To 
uncover the mechanism of this action we studied the cell signalling pathways 
involved in neuronal spike formation and differentiation in two types of neuronal cells 
(PC12 and N2a) and the interaction of militarinone A with associated pathways. The 
increased neuronal outgrowth could not be confirmed as a general activity of 
militarinone A, as this effect was only transiently seen in PC12 cells and all other cell 
lines tested underwent apoptosis within 24h. We propose that this difference is due 
to varying constitutive levels of p53.  
Furthermore, an alkaloid from the traditional European medicinal plant Isatis tinctoria 
was analysed. Isatis tinctoria contains several known anti-inflammatory components, 
namely, tryptanthrin, indirubin, and indolinone. In a previous study, indolinone was 
shown to inhibit degranulation of mast cells and this anti-allergic effect of indolinone 
should be further characterised. We confirmed the initially observed stabilising effect 
on mast cells of a different species and in a different assay set-up and showed that 
indolinone efficiently blocked PtdInsP3 production due to inhibition of all class I PI3-
kinases, therefore preventing activation of Akt and subsequent mast cell 
degranulation. The concentrations necessary to obtain the observed effect in vitro, 
however, were too high to consider in vivo testing.  
Since mast cell degranulation depends on phosphoinositide signalling we studied 
phosphosinositide levels in cells upon stimulation. For this purpose, we developed a 
method that allows individual analysis of all phosphoinositides, including all PtdInsP- 
and PtdInsP2-isomers. This novel method, based on ion-pair chromatography and 
ESI-MS detection, offers substantial perspectives for application in phosphoinositide-
signalling research as it allows relative quantification of all the different PIs in cells.  
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Zusammenfassung  
 
Naturstoffe spielen eine wichtige Rolle für die Entwicklung neuer Medikamente als 
Leitstrukturen sowie als Hilfsmittel in der Grundlagenforschung. In vorangehenden 
Arbeiten haben zwei unlängst isolierte Naturstoffe, Militarinon A und Indolinon, 
biologische Aktivitäten gezeigt. Diese Aktivitäten wurden auf der Ebene der 
Signaltransduktionswege in dieser Arbeit genauer untersucht.  
Das aus dem entomogenen Pilz Paecilomyces militaris stammende Alkaloid 
Militarinon A, wurde ursprünglich in einem Screening für neurotrophe Aktivität 
entdeckt, bei dem es die Bildung neuronaler Auswüchse in PC12 Zellen stimulierte. 
Diese induzierte Bildung von Dendriten konnte jedoch nur für diese spezifische 
Zelllinie nachgewiesen werden, während andere Zellen Apoptose eingingen. Wir 
konnten zeigen, dass diese unterschiedlichen Reaktionen auf verschiedenen 
konstitutiven Expressionslevel von p53 beruhen.  
Des weiteren wurde die Wirkungsweise von Indolinon, einem Alkaloid aus der 
traditionellen, europäischen Heilpflanze Isatis tinctoria, in dieser Arbeit analysiert. 
Isatis tinctoria enthält einige bekannte, entzündungshemmende Substanzen wie 
Tryptanthrin, Indirubin und Indolinon. In einer früheren Studie wurde gezeigt, dass 
Indolinon die Degranulierung von Mastzellen hemmt und diese anti-allergische 
Wirkung sollte nun näher untersucht werden. Die Mastzellstabilisierende Wirkung 
von Indolinon konnte bestätigt werden. Wir zeigten, dass Indolinon die Bildung von 
PtdInsP3 durch Hemmung aller Klasse I PI3-Kinasen effizient inhibiert. In Folge 
dessen werden die Phosphorylierung von Akt sowie die Degranulierung verhindert. 
Die für eine deutliche Wirkung in vitro benötigten Konzentrationen waren jedoch zu 
hoch um für eine in vivo-Anwendung in Frage zu kommen. 
Da die Degranulierung von Mastzellen abhängig von Menge und Phosphorylierungs-
grad von Phosphatidylinositolen (PIs) ist, haben wir deren Level in stimulierten Zellen 
untersucht. Dazu wurde eine analytische Methode entwickelt, durch die alle 
Phosphphatidylinositole  aufgetrennt und identifiziert werden können, insbesondere 
auch die PtdInsP- und PtdInsP2-Isomere. Diese neue Methode, basierend auf Ionen-
Paar Chromatographie und ESI-MS Detektion, eröffnet neue Perspektiven in der 
Erforschung der Phosphoinositol-Signaltransduktionswege, da eine relative 
Quantifizierung einzelner PIs möglich ist.  
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 A.    INTRODUCTION  
 
1 Natural Products in Research and Drug Discovery 
 
˝Embrace the Challenge˝ 
-Teachings of Anusara Yoga 
 
 
The therapeutic use of plants is as old as human civilisation. Even today plants 
remain the primary sources of health care for most people in the world. It is estimated 
that around 80% of the world’s population rely mainly on traditional medicine for their 
primary health care (Wang, 2008). Over the centuries, natural products have 
provided a tremendous amount of substances that serve as medicine or as lead 
structure for drug development. Around one third of the currently marketed drugs 
have structures that are related or derived from natural products (Onaga, 2001).  
 
1.1 History 
Natural products have been the first and, for a long time, sole source of medicine. 
The exploitation of traditional medicines for the development of modern drugs 
produced the first commercially available pure drug substances. The isolation of 
morphine from the opium latex by the German Pharmacist Sertürner in 1805 could be 
seen as the start of pharmaceutical natural product research. Shortly thereafter the 
isolation of many other substances followed, atropine in 1819, quinine and caffeine in 
1820, and digitoxin in 1841 (Potterat and Hamburger, 2008). Quinine was isolated in 
1820 from the bark of several Cinchona species that have been used by Peruvian 
Indians to treat shivering and malarial fevers (Corson and Crews, 2007; Greenwood, 
1992). In 1826, quinine and morphine became the first commercially available pure 
natural compounds produced by Caventou and Merck, respectively (Newman, 2000; 
Potterat and Hamburger, 2008). 
 
The synthetic modification of salicylic acid to acetylsalicylic acid in 1897, and the 
modification of morphine into diacetylmorphine (heroin) in 1898 by Hoffmann at 
Bayer AG produced the first semi-synthetic natural-product derived drugs (Schmidt, 
2008; Sneader, 2000).  
-1-
 The progression of the role of natural products in drug discovery (Figure 1) 
proceeded from the traditional use of whole plants and plant extracts to the isolation 
and identification of the active principle pure compounds, to the application of 
derivatised, optimised molecules, and finally to the use of natural products as leads 
for medicinal chemistry. 
 
 
Figure 1: Diagram describing the various roles of natural products in drug discovery and development 
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 1.2 Today 
After decades of very successful drug discovery and development, the 
pharmaceutical industry downscaled natural product research in the late 1990s in 
favour of automated high throughput screening (HTS) of compound libraries (Baker, 
2007). Compound libraries assembled with the aid of combinatorial chemistry were 
thought to produce more hits than ‘old fashioned’ natural products. Despite this 
decline in the use of natural products in drug discovery, newly marketed drugs 
derived from natural compounds hold about the same share as before (Newman, 
2003). 
The numerous and successful discoveries of compounds in the early times of 
modern drug discovery were quite exclusively based on the traditional use of the 
plant (Rishton, 2008). Of all known organic molecules, only 1% are natural products, 
99% are synthetic (von Nussbaum, 2006), but more than one third of all drug sales 
are based on natural products (Newman, 2003). How can these striking numbers be 
explained? Evolutionary selection is the answer; nature’s own high-throughput 
screening has optimized these biologically active compounds (Paterson and 
Anderson, 2005). Especially the numerous compounds with antibacterial activity do 
not surprise, as fighting for space and resources, and against other organisms, plays 
a pivotal role in survival.  
Early attempts to apply HTS to botanical extracts were faced with many difficulties. 
With the introduction of biochemical assays in the 90s, the screening process had 
shifted from functional cellular assays to cell-free biochemical assay formats, which 
are very sensitive and prone to artefacts. The typically coloured plant extracts are not 
compatible with such screening assays due to interference with detection caused by 
colour, fluorescence, or quenching effects of components in the extract. Moreover 
the complexity of extracts potentially induces aggregation of components, chemical 
reactions within the assay or difficulties of solubility in assay buffer (Rishton, 2008). 
Pre-fractionation or purification to reduce the chemical complexity of the extracts 
needs to be implemented before HTS can be performed. This is time-consuming and 
laborious and generally reduces the attractiveness of screening of natural 
compounds. Another approach is to use the power of combinatorial chemistry in 
combination with knowledge on active natural products and create a library that 
extends upon the structural properties of known natural compounds. This strategy 
-3-
 generates libraries with enhanced specificity and selectivity (Koehn and Carter, 
2005).  
 
1.3 Marketed Drugs 
Here I briefly describe selected examples of successfully marketed drugs that are 
natural compounds, derivatives of natural compounds, or synthetic molecules for 
which the lead was a natural product. The focus here is on some more recent drugs 
that had a major impact on human lives, while the more historical and well-known 
examples such as morphine, penicillin, quinine, streptomycin and others are left out. 
 
1.3.1 Lovastatin (FDA Approval 1987) 
Since the discovery of a correlation between high cholesterol levels and coronary 
heart disease in the 1950s, the lowering of high cholesterol levels with drugs has 
been pursued (Kannel, 1995; Keys, 1984). The cholesterol biosynthesis is a complex 
process involving more than 30 enzymes and was discovered during the 1950s and 
60s (Russell, 1992). HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase 
is the rate-limiting enzyme of the biosynthetic pathway and hence most suitable for 
inhibition. Furthermore, when HMG-CoA reductase is inhibited an alternative 
pathway for degradation of the substrate is available which prevents accumulation of 
HMG-CoA.  
A potent inhibitor of HMG-CoA reductase, compactin (later additionally named 
mevastatin (Figure 2)), was found in a broth of Penicillium citrinum (Endo, 1976). 
Soon after, in 1978, another HMG-CoA reductase inhibitor was discovered in the 
Merck laboratories from Aspergillus terreus and named mevilonin (lovastatin (Figure 
2)) (Alberts, 1980). Compactin was highly effective in lowering plasma cholesterol in 
animal models as well as patients with hypercholesterolaemia (Kuroda, 1979; 
Mabuchi, 1981; Mabuchi, 1983; Tsujita, 1979; Watanabe, 1981). However, 
compactin was withdrawn from clinical trials in 1980 due to unpublished reasons 
(Tobert, 2003). Because of the structural similarity between compactin and lovastatin, 
clinical studies with lovastatin had to be stopped as well. After additional animal 
studies and some investigation in small-scale high-risk patient studies, clinical 
development was re-launched in 1983 until, finally, in 1987 the FDA (U.S. Food and 
Drug Administration) approval for lovastatin was obtained (Illingworth and Sexton, 
1984; Thompson, 1986). Soon after, other statins from microbial sources were 
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 released. Simvastatin (Figure 2) entered the market in 1988, it is semi-synthetically 
derived from lovastatin introducing a minor side chain modification. In 1991 
pravastatin followed, with a modification in the side chain ring. Later, synthetically 
designed products with different chemical structures followed; fluvastatin in 1994, 
atrovastatin in 1997, cerivastatin in 1998 and rosuvastatin in 2003.  
 
Figure 2:  Structures of compactin, mevilonin and simvastatin 
 
The mechanism of action of statins goes beyond blocking cholesterol biosynthesis. 
Inhibition of HMG-CoA reductase reduces levels of mevalonate, which in turn leads 
to upregulation of low-density lipoprotein (LDL) receptors on hepatocytes. The 
upregulation of LDL receptors increases the uptake of LDL from blood, the major 
marker of elevated cholesterol levels (Brown and Goldstein, 1980; Reihner, 1990). 
With the discovery of lovastatin it was for the first time possible to achieve large 
reductions in plasma cholesterol of up to 40% (Tobert, 1982). The treatments 
formerly available were all of limited efficacy or tolerability. The bile acid sequestrants 
are moderately effective and poorly tolerated due to gastrointestinal side effects 
whereas fibrates produce a rather small reduction in LDL-cholesterol but are well 
tolerated and widely used. The statins revolutionised the treatment of 
hypercholesterinaemia and annual sales are > 15 billion US $ (Downton and Clark, 
2003). In 2001, however, cerivastatin, only introduced in 1998, had to be withdrawn 
from the market due to severe side effects of rhabdomyolysis which occurred in 
concomitant use with gemfibrozil (Furberg and Pitt, 2001). The mechanism for this 
side effect still remains elusive but further studies demonstrated the safety of other 
statins. Nevertheless myalgia as a side effect under statin therapy occurs but seldom 
develops into severe myolysis. 
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 The statins became the most effective drugs so far for preventing and halting 
arteriosclerosis. Despite the wide use of these drugs it is believed that they are 
underutilised in patients who are free of symptoms with only moderately elevated 
cholesterol levels. This led to the decision to approve simvastatin as an ‘over-the-
counter’ (OTC) medicine, available without prescription, in the UK in July 2004 (Link, 
2004; Roberts, 2004).  
 
1.3.2 Paclitaxel (FDA Approval 1992) 
Plants have a long history in the use of cancer treatment. The first plant derived drug 
to treat cancer was the Vinca alkaloid vincristine, which was approved for clinical use 
in 1963. A more recent discovery of a plant-derived chemotherapeutic agent was 
paclitaxel (Figure 3) from Taxus brevifolia bark (Wani, 1971). Paclitaxel was shown to 
stabilise microtubule assembly, whereas Vinca alkaloids and colchicin prevent the 
assembly of microtubules (Schiff, 1979; Schiff and Horwitz, 1981). Even in absence 
of essential GTP, paclitaxel promotes microtubule assembly. Although paclitaxel 
shows no structural resemblance to GTP, it is able to interact specifically with the β-
subunit of microtubules, a region that is associated with GTP binding and hydrolysis 
(Snyder, 2001). The stabilisation of microtubules by paclitaxel forces the tumour cell 
into multiple DNA replication cycles that eventually initiate apoptosis (Stewart, 1999). 
 
 
Figure 3: Structure of paclitaxel 
 
Clinical trials with paclitaxel were started in the early 1980s, and FDA approval for 
treatment of refractory ovarian cancer was granted in 1992. Since the introduction of 
paclitaxel to the treatment of ovarian cancer the survival rate has more than doubled 
(Crown and O'Leary, 2000), and further applications have been approved since. 
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 Today, paclitaxel is also used in the treatment of breast and colon cancers as well as 
Kaposi’s sarcomas of HIV infected patients (Oberlies and Kroll, 2004).  
Preparation of sufficient amounts of paclitaxel to launch clinical studies was nearly 
impossible, as isolation from the bark results in very low yields and excoriation 
causes the trees to die. In 1986, the precursor deacetyl baccatin III was isolated from 
the needles of Taxus baccata, and the semi-synthetic approach lead to the 
production of sufficient amount of paclitaxel from renewable sources (Gueritte-
Voegelein, 1991). Furthermore, semisynthesis enabled the creation of an analogue 
of paclitaxel, docetaxel (Bissery, 1991), which entered the market in 1996. 
From the perspective of both basic science and clinics, paclitaxel has led to 
significant progress in understanding and treating cancer.  
 
1.3.3 Sirolimus, Rapamycin (FDA Approval 1999) 
In this section, the clinical aspects of sirolimus are described, whereas the molecular 
and signalling-related aspects are discussed later in this chapter. 
Rapamycin (Figure 4) was discovered in the 1970s as a potent antifungal metabolite 
of the bacterial strain Streptomyces hygroscopicus and was named after the origin of 
the sample, the Easter Island Rapa Nui (Vezina, 1975). Its clinical development as 
an antifungal drug was stopped when its strong antiproliferative and 
immunosuppressive effects were detected (Chang, 1991; Eng, 1984). The substance 
fell into oblivion until studies on the mechanism of action led to the identification of its 
target (target of rapamycin, TOR) in 1992 (Heitman, 1992). Later, the compound was 
also named sirolimus due to its structural similarities with tacrolimus, which was 
discovered in 1987.  
The immunosuppressive activity of rapamycin is due to its blocking of interleukin 2 
(IL2) mediated T-cell proliferation and activation (Dumont, 1990) thereby preventing 
allograft rejection after organ transplantation. The combination of rapamycin with 
calcineurin inhibitors such as cyclosporine A or tacrolimus results in significant 
synergistic effects that improve the prevention of organ rejection (Kahan, 1998). In 
1997 rapamycin/sirolimus obtained FDA approval for preventing host-rejection of 
kidney-transplants. Further studies address the use of rapamycin in autoimmune 
diseases such as psoriasis, multiple sclerosis or rheumatoid arthritis (Foroncewicz, 
2005; Tsang, 2007) and are still ongoing. The additional inhibitory effects of 
rapamycin on the proliferation of vascular smooth muscle cells led to the 
-7-
 development of rapamycin as antirestenosis drug, and coronary-artery stents 
releasing rapamycin are approved in surgery since 2003 (Morice, 2002).  
 
Figure 4: Structure of rapamycin 
 
1.3.4 Artemisin (Swissmedic Approval 2000, no FDA Approval) 
The Chinese medicinal herb qing hao (Artemisia annua) was traditionally used to 
reduce fever and, in 1596, was mentioned for the first time to treat malaria (Klayman, 
1985). In 1972, Chinese scientists managed to isolate the active principle of the herb 
and called it qinghaosu, meaning ‘the active principle of qing hao’ (1979), named 
artemisinin (Figure 5) for the Western world. The structure was elucidated in 1980 
and revealed to be a sesquiterpene structure with an unusual endoperoxide group 
(Acton and Klayman, 1985). The high lipophilicity of artemisinin made administration 
as a drug difficult; therefore, various derivatives were synthesised, including 
arthemether, arteether and artesunate (Figure 5).  
 
Figure 5: Structures of artemisinin, artemether, and artesunate 
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The biological activity of the artemisinins depends on the cleavage of the peroxide 
bond after contact with iron-II-hem within the parasite. The generated free radical 
alkylates the hem molecule or parasite proteins (Bhisutthibhan, 1998; Olliaro, 2001). 
Inhibition of the sarco/endoplasmatic reticulum Ca2+ -ATPase (SERCA) has been 
proposed as an additional target (Eckstein-Ludwig, 2003). The active metabolite 
dihydroartemisinin kills nearly all asexual stages of parasite lifecycle in the blood, and 
also affects the gametocytes, which are responsible for the infection of the 
Anopheles mosquito and transmit the disease. Furthermore the artemisinins act 
faster than any other antimalarial drug with a fever and parasite clearance time of 
less than two days (Wiesner, 2003). However, due to the short plasma half-life of 
these drugs therapy needs to be continued for 5-7 days, or needs to be combined 
with other antimalarial drugs (White, 2008). The combination usually applied is 
artesunate-lumefantrine. In 2000 Swissmedic approved the drug for sale under the 
name Riamet; in other countries it is sold as Coartem. At the moment, Novartis is still 
awaiting FDA approval for Coartem. 
 
1.4 Promising Research  
The examples discussed here were selected for their uniqueness, as they all 
represent the first substances in clinical development with their respective mode of 
action. Mostly the understanding of their molecular target has evolved concurrently 
with the discovery of the substance and the subsequent studies of the 
pharmacological and clinical effects.  
 
1.4.1 Fingolimod  
Fingolimod is a synthetic compound inspired by the structure of myriocin (Figure 6), 
which is produced by the fungus Isaria sinclarii (Fujita, 1994). Myriocin is a structural 
analogue of sphingosine, a C18 amino alcohol, which is a part of sphingolipids. In 
vivo myriocin caused severe intoxication resulting in death of the animals. Because 
of potent immunosuppressive activity in vitro, synthetic modifications were introduced 
to reduce toxicity (Chiba, 1996). Fingolimod (FTY720 (Figure 6)) is such a synthetic 
analogue that only obtains its immunosuppressive activity after phosphorylation by 
sphingosine kinase 2 in vivo (Suzuki, 1996; Zemann, 2006). The biologically active 
fingolimod-phosphate binds to four of the five known sphingosine-1-phosphate (S1P) 
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 receptors, all but S1P2 (Rosen and Goetzl, 2005). Binding of fingolimod-P results in 
internalisation and degradation of the S1P1 receptor, thus depriving the cell of the 
necessary signals for cell motility and chemotaxis, and leading to down regulation of 
the receptor (Cyster, 2005). Therefore, circulating lymphocytes are retained in lymph 
nodes, resulting in reduction of peripheral lymphocytes (Mandala, 2002).  
Clinical trials of fingolimod for suppression of transplant rejection were discontinued 
in 2006 due to a lack of advantage over the existing treatments (Salvadori, 2006). 
However, trials for treatment of relapsing multiple sclerosis still are ongoing and 
preliminary data looks very promising (Kappos, 2006).   
 
Figure 6: Structures of sphingosine, myriocin and fingolimod 
 
1.4.2 Gossypol  
Gossypol (Figure 7) is a polyphenolic compound isolated from cottonseeds or crude 
cotton oil that was described and named already in 1899 by Marchlewski (Withers 
and Carruth, 1915). Of the two enantiomers of gossypol, (-)-gossypol and (+)-
gossypol only (-)-gossypol shows biological activity in vivo, although this was only 
discovered after separation of the two isomers succeeded in 1985 (Zheng, 1985). 
The toxic effects of gossypol, however, are long known and for that reason 
cottonseeds and cotton oil cannot be used for animal feeding or aliment. As a result 
of a general survey of public health in Chinese rural communities in the 1950s the 
use of crude cotton oil was linked with reduced male fertility (Kong, 1986). Clinical 
studies for a male contraceptive agent with over 8000 precipitants showed an overall 
antifertility effect of 99.9 % (1980). Despite these promising initial results clinical 
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 studies as male contraceptive were discontinued in 1998 due to sustained infertility 
after prolonged use of gossypol (Porat, 1990). One possible explanation for the 
inhibition of spermatogenesis is the suppression of telomerase activity by gossypol 
(Moon, 2008). The reverse transcriptase telomerase is only found in embryonal, 
gonadal and cancer cells, as it enables unlimited cell division (Mego, 2002). 
Telomerase inhibition, however, is an interesting target in cancer therapy and 
gossypol was therefore tested in several cancer models as well as in vivo against 
diffuse large cell lymphoma, head and neck squamous cell carcinoma, and breast 
cancer (Mohammad, 2005; Van Poznak, 2001; Wolter, 2006).  
 
Figure 7: Structure of gossypol 
 
In a screening of a small natural product library gossypol showed potent inhibition of 
the antiapoptotic proteins Bcl-2 and Bcl-xL (Kitada, 2003). It binds to the BH3 binding 
domain of the antiapoptotic Bcl-2 family members, where the pro-apoptotic Bcl-2 
family member Bid would bind to induce apoptosis. Gossypol is the first substance 
found to mimic BH3-binding to Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 and serves now as 
lead substance for further development of small inhibitory molecules (Marzo and 
Naval, 2008). Currently, gossypol is evaluated as the first Bcl-2 inhibitor in clinical 
trials against various cancers.    
 
1.4.3 Bryostatin-1  
The macrocyclic lactone bryostatin-1 (Figure 8) was isolated and identified in 1982 by 
Pettit et al. (Pettit, 1982) from the marine ‘moss-animal’ (Ectoprocta or Bryozoa) 
Bugula neritina, which was collected in the Gulf of Mexico in 1968. Bryozoans are 
aquatic colonial animals that are abundant in marine enviroment. Already in 1970 the 
antineoplastic effect of Bugula neritina extract was shown to lead to prolonged 
survival in a leukaemia mouse model (Pettit, 1970). Like the phorbol esters, 
-11-
 bryostatin-1 can be a potent activator of protein kinase C (PKC) (Berkow and Kraft, 
1985). Prolonged exposure to bryostatin-1, however, induces PKC inhibition by 
degradation and subsequent downregulation of PKC (Isakov, 1993). Furthermore, 
bryostatin-1 inhibits phorbol ester induced tumourgenesis and differentiation of 
promyelocytic leukaemia cells (Hennings, 1987; Kraft, 1987). Bryostatin-1 was shown 
to bind to the ‘phorbol ester receptor’, which means the diacylglycerol (DAG)- binding 
pocket of PKC (de Vries, 1988) and, when bound to PKC, induces PKC-degradation 
by ubiquitination (Lee, 1996a; Lee, 1996b).  
 
Figure 8: Structures of bryostatin-1 and its analogue, synthesised by Wender 2004. 
 
Clinical phase II studies with single-agent bryostatin-1 have been conducted for 
melanoma, renal cell carcinoma, colorectal cancer, and non-Hodgkin’s lymphoma, 
mostly with disappointing results (Kortmansky and Schwartz, 2003). But co-
administration of bryostatin-1 with other cytotoxic agents produced promising results; 
particularly the combinations of bryostatin-1/paclitaxel and bryostatin-1/temsirolimus 
proved to be effective and are currently evaluated in clinical trials (Ku, 2008).  
Development of analogues of bryostatin-1 (Figure 8) by Wender et al. (Wender, 
2004) led to simplifications of parts of the structure that allow large-scale synthesis 
but preserve the crucial parts for bioactivity (Paterson and Anderson, 2005). 
Additionally, these studies created a better understanding of the structure-activity 
relationship of PKC inhibition and most likely will generate bryostatin analogues for 
clinical development. 
Besides development as an anticancer drug bryostatin-1 is also under investigation 
as a central nervous system (CNS) drug (Sun and Alkon, 2006). Numerous reports 
imply a critical role of PKC malfunctions in the development of Alzheimer’s disease 
(AD) (Cole, 1988; Favit, 1998; Lee, 2004). The PKC modulating effects of bryostatin-
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 1 seems to promote memory-enhancing and mood regulation effects (Sun and Alkon, 
2005). Although passage of Bryostatin-1 through the blood-brain barrier was not 
determined in this study, previous studies with mice indicate that bryostatin-1 can 
pass across the blood brain barrier, but the brain levels of the drug were much lower 
than plasma levels (Zhang, 1996). Development of analogues of bryostatin-1 may 
result in compounds with improved CNS permeability and that could produce the 
desired effects at much lower doses.  
 
1.5 Natural products as research tool 
The elucidation of signal transduction pathways uses several tools of molecular 
biology, such as gene knockdown, overexpression of proteins, and the use of specific 
inhibitors of certain signalling molecules. All have been helpful to trace the function of 
pathways in vivo (Levine, 2007). Especially inhibitors of specific signal transduction 
molecules have offered opportunities for studying the signal transduction 
mechanisms. The example of rapamycin, its biological activity, the detection of its 
target mTOR, the mammalian target of rapamycin, and the following identification of 
a novel signalling cascade involved in fundamental processes of growth and 
development, shows the value of natural products like rapamycin as research tool.  
 
1.5.1 Rapamycin 
Rapamycin (also named sirolimus) was discussed as an immunosuppressive 
treatment earlier in this chapter (Chapter 1.3.3; Figure 4). Here the impact of the 
discovery of rapamycin on biological research shall be highlighted.  
The target of rapamycin (TOR) was identified in the budding yeast Saccharomyces 
cervisiae in the 1990s (Heitman, 1992), and subsequent studies in mammalian cells 
led to the identification of the mammalian TOR (mTOR) (Sabers, 1995). Since 
several groups cloned the gene at about the same time, TOR is also known as FRAP 
(FKBP12-rapamycin-associated protein), RAFT (rapamycin and FKBP12 target), 
RAPT (rapamycin target), and SEP (sirolimus effector protein) (Fingar and Blenis, 
2004). TOR is a 290 kDa large member of the PI3K-kinase-related-kinase (PIKK) 
superfamily and is 40-60% identical amongst mammals, flies, worms and yeast 
(Wullschleger, 2006). Two different TOR complexes are formed, in yeast containing 
two different TORs, TOR1 and TOR2. In mammals mTOR is associated with raptor 
forming the mTORC1 complex or with rictor, forming the mTORC2 complex. In cells 
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 rapamycin forms a complex with a cofactor, FKBP12, and binds to TOR resulting in 
the inhibition of TOR. In mammalian cells rapamycin only inhibits the mTORC1 
complex, but not the mTORC2.  
Rapamycin treatment results in cell cycle arrest in late G1 phase (Dumont and Su, 
1996), because mTOR initiates the signal for translation of key mRNAs required for 
cell cycle progression from G1 to S phase. In addition, rapamycin blocks cyclin-
dependent activation and accelerates the turnover of cyclin D, resulting in growth 
arrest in G1 phase of the cell cycle (Rowinsky, 2004).  
 
1.5.2 Wortmannin 
The fungal metabolite wortmannin (Figure 9) was isolated from Talaromyces 
wortmanni, a Penicillium strain, in 1957 by Brian and Norris (Brian, 1957) and the 
structural determination as a furanosteroid followed in 1968 (MacMillan, 1968). 
Wortmannin was found to inhibit phosphoinositide 3-kinases (PI3-kinases), where it 
binds colvalently to the p110α subunit of the PI3-kinase into the ATP-binding site and 
blocks it with an IC50 of 5 nM (Wipf and Halter, 2005; Wymann, 1996). Other potential 
targets as protein kinases remain fairly unaffected in these concentrations (Bain, 
2007). Therefore, the compound has been a useful tool for investigations of signal-
transduction pathways involving PI3-kinase activity (Cardenas, 1998). Due to the 
high toxicity the clinical use of wortmannin never became possible, and due to lack of 
isoform specificity all essential PI3-kinase isoforms are equally inhibited. Isoform 
specific inhibitors of PI3-kinase γ are in clinical development.  
                     
Figure 9: Structures of wortmannin (left) and staurosporine (right) 
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 1.5.3 Staurosporine 
Staurosporine (Figure 9) is an alkaloid isolated from a Streptomyces strain that was 
discovered in 1977 in a screening for PKC inhibitors (Omura, 1977). The compound 
turned out to be a potent, but not selective, inhibitor of protein kinases, competing 
with ATP for binding (Lamers, 1999). Staurosporin shows nanomolar activity against 
many protein kinases and has become the ‘lead’ inhibitor for the design of protein 
kinase inhibitors. Various analogues have been synthesised to obtain better 
selectivity, but the precise mechanisms to achieve selectivity remains elusive. The 
recently synthetically derived analogue of staurosporine, Enzastaurin (LY 315615) 
has now entered Phase III clinical trials for prevention of relapse in patients with 
some specific tumours (Butler and Newman, 2008; Graff, 2005). Staurosporine was 
also found to be a potent inducer of apoptosis through caspase-dependent, as well 
as independent pathways (Belmokhtar, 2001). It has been shown to induce apoptosis 
in all cell types tested to date and therefore became a widely employed inducer of 
mitochondria-dependent apoptosis in research (Kruman, 1998; Leist and Jaattela, 
2001).  
 
1.5.4 Phorbol Esters 
Phorbol esters (Figure 10) activate PKC in a DAG-mimicking manner. The tumour 
promoting activity of Croton oil from Croton tiglium has been observed by Berenblum 
in 1941 (Berenblum, 1941) and was linked to PKC in 1988 (Nishizuka, 1988). The 
widely used active phorbol ester TPA (4β-12-O-tetradecanoylphorbol-13-acetate, 
also known as PMA (phorbol 12-myristate-13-acetate)) acts as an analogue of the 
natural PKC substrate, DAG, but is a much more potent activator of PKC. Prolonged 
incubation with phorbols, however, results in down-regulation of PKC (Silinsky and 
Searl, 2003).  
  
Figure 10: Structure of the phorbol ester 4β-12-O-tetradecanoylphorbol-13-acetate (TPA) 
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 In vivo the phorbols do not induce tumour formation but promote tumour growth 
following exposure to carcinogens. Thus, they can be characterised as co-
carcinogenics (Goel, 2007).  
 
1.5.5 Okadaic Acid 
Okadaic acid (Figure 11) is a marine natural product isolated from the sponge 
Halichondria okadai (Tachibana, 1981) that shows cytotoxic activity against several 
carcinoma and leukaemia cell lines. It was subsequently found that okadaic acid 
possesses a tumour promoting activity similar to phorbol esters (Nishizuka, 1984). 
But in 1988 okadaic acid was found to inhibit protein serin/threonine phosphatases 
(Bialojan and Takai, 1988) and not PKC. The serine/threonine phosphatase PP2A, 
however, is physically associated with PKCα, maintaining it in a hypo-phosphorylated 
state and, when inhibited, leads to hyper-activity of PKC (Boudreau and Hoskin, 
2005). Okadaic acid has since been used as a key laboratory tool for identifying and 
studying the events associated with protein serine/threonine phosphatase (PP) 
inhibition, especially of the two major members PP1 and PP2A (Gehringer, 2004). 
For clinical application, however, okadaic acid lacks sufficient specificity and shows 
tumour-promoting activity.  
 
Figure 11: Structure of the marine phosphatase inhibitor okadaic acid 
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2 Signal transduction pathways 
 
˝Flowing with Grace˝ 
-Teachings of Anusara Yoga 
 
 
2.1 Apoptosis 
The term apoptosis was introduced in a paper by Kerr, Wyllie, and Currie in 1972 
(Kerr, 1972) to describe a form of programmed cell death with distinct morphological 
features such as cell shrinkage, membrane ruffling (also named membrane 
blebbing), chromatin condensation, and DNA fragmentation (Rich, 1999). In 
multicellular organisms the process of apoptosis is fundamental for development and 
maintenance of homeostasis, when excessive, infected or aged cells need to be 
eliminated (Movassagh and Foo, 2008). In a healthy human adult around 10 million 
cells per day undergo apoptosis (Curtin and Cotter, 2003). Apoptosis is a active 
cellular process, in contrast to necrosis, in which cell death is uncontrolled and leads 
to loss of membrane integrity, swelling and disruption of the cells with subsequent 
inflammatory response in the surrounding.  
There are two major apoptosis inducing pathways, the extrinsic or death receptor 
pathway and the intrinsic or mitochondrial pathway. The extrinsic pathway is initiated 
by extrinsic signals leading to activation of death receptors, such as Fas (also named 
CD95 or Apo-1), tumour necrosis factor receptor (TNFR), and TRAIL-receptor (TNF-
related apoptosis ligand). The intracellular death domain recruits and activates 
caspase-8, which leads to subsequent activation of downstream caspases (Lavrik, 
2005). Whereas the intrinsic pathway involves non-receptor-mediated intrinsic 
signals induced by DNA damage, growth factor deprivation, or oxidative stress that 
lead to activation of the Bcl-2 family proteins and results in release of cytochrome c 
from the mitochondria and consequential activation of caspases (Figure 12). The 
pathways of apoptosis converge on the activation of caspases and influence each 
other (Igney and Krammer, 2002). 
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Figure 12: Simplified diagram of apoptosis pathways (built with templates from 
www.cellsignaling.com). 
 
2.1.1 Bcl-2 family 
The first protein identified to be involved in apoptosis was Bcl-2, initially characterised 
as proto-oncogene in human lymphoma cells (hence the encoding gene was named 
B-cell lymphoma-2, bcl-2) (Tsujimoto and Croce, 1986; Vaux, 1988). To date about 
20 Bcl-2 family members are identified and can be divided into two functional groups 
with either anti- or pro-apoptotic activity. The anti-apoptotic proteins Bcl-2, Bcl-xL, 
Bcl-w, and others contain at least four highly conserved bcl-2 homology (BH) 
domains. Bcl-2 is exclusively found associated with intracellular membranes, 
including the outer mitochondrial membrane, the endoplasmatic reticulum and the 
nuclear envelope (Krajewski, 1993). Whereas Bcl-xL is additionally found soluble in 
the cytosol, and translocation from the cytosol to the mitochondrial outer membrane 
is induced during apoptosis (Hsu, 1997). The pro-apoptotic subfamily can be further 
divided into two groups, the multidomain proteins (or BH123), including Bax, Bak, 
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 and others, and the BH3-only proteins, that contain only one BH3 motif such as Bid, 
Bim, Bad, PUMA, Noxa, and some more (Figure 13) (Antonsson, 2004).  
 
Figure 13: Mitochondrial pathway of apoptosis (modified from a model on www.cellsignaling.com).  
The BH3-only proteins are pro-apoptotic and function as initial sensors of apoptotic 
signals, activating the pro-apoptotic family members. The anti-apoptotic family 
members, such as Bcl-2 and Bcl-xL bind to and thereby inhibit the pro-apoptotic 
family members Bax and Bak. Activation of the BH3-only proteins results in liberation 
of Bax and Bak and thus initiation of apoptosis. The precise mechanism for the 
activation of Bax and Bak remains unclear and ‘constitutes the holy grail of apoptosis 
research’ (Youle and Strasser, 2008). Liberation of Bax and Bak from binding to their 
anti-apoptotic inhibitors Bcl-2 and Bcl-xL leads to several conformational changes 
and results in homo-oligomerisation (Chipuk, 2006; Newmeyer and Ferguson-Miller, 
2003). These oligomers are believed to build pores in the outer mitochondrial 
membrane and induce the mitochondrial outer membrane permeabilisation (MOMP), 
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 which leads to the release of cytochrome c and other proteins residing in the 
mitochondrial intermembranous space, such as apoptosis inducing factor (AIF) and 
Smac/DIABLO, an inhibitor of IAPs (inhibitors of apoptosis) (Green and Kroemer, 
2004). Progression of apoptosis through activation of caspases, mitochondrial 
decomposition and initiation of DNA fragmentation result from these released 
molecules (Figure 13). 
 
2.1.2 Cytochrome c 
Cytochrome c is a haem-containing protein that participates in the mitochondrial 
electron-transport chain, using its heam group to shuttle electrons. However, upon 
activation of the intrinsic pathway and MOMP, cytochrome c is released to the cell 
plasma where it binds to apoptotic protease-activating factor-1 (Apaf1) that 
oligomerises and forms a complex, called apoptosome, which recruits and activates 
procaspase-9 (Li, 1997). Active caspase-9 in turn activates downstream effectors, 
such as caspase-3 and -7 that lead to execution of apoptosis (Figure 13).  
 
2.1.3 Caspases 
Caspases are cysteinyl-aspartic acid proteases that play a key role in apoptotic cell 
death and are normally present in healthy cells as inactive precursor zymogens. To 
date 11 caspases have been identified in humans (Degterev, 2003). Three groups of 
caspases can be formed: the cell death initiators, caspase -8, -9, -2, and -10, the cell 
death executors, caspases-3, -6, and -7, and the inflammatory caspases, not 
involved in apoptosis (caspase-1, -4, -5, -11, -12, -13, -14) (Rupinder, 2007). 
The extrinsic, death receptor induced apoptosis pathway activates primarily caspase-
8. Ligation of death receptors (Fas, TNFR, TRAILR) induces conformational changes 
and recruits adaptor proteins such as Fas-associated death domain (FADD) to the 
receptor. There, together with procaspase-8, a complex is formed, called death 
inducing signalling complex (DISC) that leads to activation of caspase-8 (Figure 14). 
Caspase-8 in turn activates the executive caspase-3 that directly triggers chromatin 
condensation, cleavage of diverse cellular proteins and DNA fragmentation (Porter 
and Janicke, 1999). Furthermore caspase-8 can activate the BH3-only protein Bid, 
which leads to its mitochondrial translocation and to activation of the intrinsic 
pathway (Luo, 1998).  
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Figure 14: Extrinsic pathway and possible points of inhibition (Figure constructed with parts from 
www.cellsignaling.com). 
 
2.1.4 IAPs  
Although the major way to regulate caspase activity is by proteolytic cleavage, there 
are other regulatory pathways. Most importantly the inhibitor-of-apoptosis proteins 
(IAPs) that are able to sequester and inactivate pro-caspases and caspases 
(LaCasse, 1998). To date eight human IAPs have been identified, including XIAP, 
cIAP1, cIAP2, and Survivin. Activity of IAPs, however, is also finely regulated during 
apoptosis. The ‘second mitochondrial-derived activator of caspases’ (smac, also 
called DIABLO, ‘direct IAP binding protein with low pI’) is released along with 
cytochrome c from the mitochondria upon apoptotic stimuli and binds to IAPs in a 
manner that liberates caspases from IAP (Figure 14) (Adrain, 2001; Salvesen and 
Duckett, 2002).  
 
2.1.5 c-FLIP 
Cellular caspase-8 (FLICE)-like inhibitory protein (c-FLIP) is a protein associated with 
the DISC, downstream of Fas, TRAIL or TNF receptors (Hyer, 2006; Jin, 2005) and is 
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 a main regulator of caspase-8 activity (Figure 14). c-FLIP exhibits a dual function of 
inhibition or activation of caspase-8 activation downstream of death receptors. In low, 
physiological concentrations (1% of caspase-8 content) there is no explicit inhibition 
of caspase-8 activation apparent. In higher concentrations, however, c-FLIP inhibits 
homodimer formation of caspase-8 and hence prevents activation (Lamkanfi, 2007). 
The induced signal leads then to activation of the NFκB pathway and therefore to 
pro-survival pathways. Several retroviruses (best characterised in Herpes virus -8) 
express FLIP (v-FLIP), which detracts the cell from apoptosis and promotes survival 
of virus-infected cells (Thome, 1997).  
 
2.1.6 AIF 
In addition to proteins that directly activate, mitochondria release proteins unrelated 
to caspase signalling, such as the apoptosis-inducing factor AIF. AIF is a 
mitochondrial flavoprotein that is localised in the mitochondrial intermembranous 
space. In healthy cells, AIF is required for efficient oxidative phosphorylation. Upon 
apoptotic insult it is released to the cytosol (Figure 13) and eventually imported into 
the nucleus, where it binds to DNA and induces caspase-independent cell death 
resulting in chromatin condensation and DNA degradation (Galluzzi, 2008). In fact, 
AIF is believed to play a major role in caspase-independent cell death (Joza, 2001). 
Mitochondrial AIF, however, has been shown to contribute to cell survival by 
protecting cells against harmful oxidative damage but in response to severe stress it 
predisposes them to more efficient death (Porter and Urbano, 2006). AIF expression 
levels in cells were shown to be regulated by the tumour suppressor p53 
(Stambolsky, 2006).  
 
2.1.7 p53 
The tumour suppressor p53 is one of the most mutated genes in human cancers 
(Vousden and Lu, 2002). Extrinsic or intrinsic stress, such as irradiation, reactive 
oxidative species (ROS), and DNA damage activates p53. Depending on cell type, 
cell environment and the kind of stress, activation of p53 leads to cell cycle arrest, 
DNA repair, senescence, differentiation or apoptosis (Vousden and Lu, 2002). In 
most cases, however, induction of p53 leads to an irreversible inhibition of cell growth 
and apoptosis. Both, loss or gain of p53 function result in aberrant cell growth, hence, 
the cellular expression and the activity of p53 are tightly regulated. The p53 protein 
-30-
 has a very short half-life and is only present at extremely low levels within the cell 
(Pietsch, 2008). Control of the function of p53 is possible at different levels and the 
most effective is the control of its plasma levels by Mdm2. Mdm2 is a ubiquitin ligase 
that binds to p53 and targets its proteosomal degradation, Mdm2 itself is a 
transcriptional target of p53, creating a autoregulatory negative feedback loop 
(Harris, 2005). The activation and stabilisation of p53 is generally associated with 
inhibition of the function of Mdm2 (Figure 15). Different stress signals allow p53 to 
escape Mdm2-mediated protein degradation and to become active. Activation of p53 
induces transcription of a myriad of proteins, such as the Bcl-2 proteins Bax, Puma, 
and Noxa, the death receptor Fas, caspases-1 and -6, PTEN and many more (Riley, 
2008).  
Apart from its functions as a transcription factor, p53 directly activates the apoptotic 
machinery by translocation to the mitochondria (Caelles, 1994). There, p53 seems to 
function analogous to BH3-only members, resulting in oligomerisation of Bak and 
Bax and leading to cytochrome c release from the mitochondria (Leu, 2004). This 
role of p53, however, has not been studies as extensively as its role as transcription 
factor and its relevance it still discussed controversially (Pietsch, 2008). 
 
 
Figure 15: Regulation of p53 
 
2.1.8 The NFκB pathway 
Tumour necrosis factor (TNF) is a multifunctional pro-inflammatory cytokine mainly 
produced by macrophages (Wajant, 2003). Besides its function as a death receptor, 
TNFR also activates NFκB and c-Jun N-terminal kinase (JNK) pathways. Unlike the 
other death receptors, Fas and TRAILR, activation of TNFR does not spontaneously 
induce cell death as, the simultaneous NFκB-activation promotes a strong pro-
survival signalling pathway and targets several anti-apoptotic proteins such as Bcl-
xL, IAP, XIAP, and FLIP (Wajant, 2003). Apoptosis is only induced when NFκB 
activation is blocked (Wang, 1996).  
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 In absence of an activating signal NFκB is sequestered in an inactive form in the 
cytoplasma by its inhibitor IκB (inhibitor of NFκB). In response to extracellular stimuli 
the IKK-complex (IκB-kinase-complex) is activated and phosphorylates IκB (Figure 
16). Phosphorylated IκB can no longer inhibit NFκB and gets degraded. Once freed 
from IκB, NFκB translocates into the nucleus, where it induces transcription of a 
range of genes that confer resistance to death-inducing signals (Li and Lin, 2008).  
 
Figure 16: Regulation of NFκB. Cytosolic NFκB is inhibited by IκB, which is degraded upon activation 
and NFκB can translocate to the nucleus to induce transcription of various proteins. 
 
2.1.9 Other cellular stress responses involved in apoptosis 
JNK signalling has been implicated in cellular stress-induces apoptosis by the fact 
that it is able to influence the activity of p53. Depending on the cellular context, JNK 
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 either destabilises p53 by promoting its degradation or stabilises p53 by 
phosphorylation (Fuchs, 1998a; Fuchs, 1998b).  
Sphingosine and ceramide belong to a group of lipids (sphingolipids) that are 
abundant in membranes and are gaining recognition as important signalling 
mediators. In healthy cells, sphingomyelin is found predominantly in the outer leaflet 
of the plasma membrane. Under stress conditions, however, sphingomyelin turnover 
is induced and leads to increased plasma levels of sphingosine and ceramide. 
Sphingosine can then be phosphorylated to sphingosine-1-phosphate (S1P) by 
sphingosine kinase (SphK). The discovery that S1P regulates cell growth and 
suppresses apoptosis triggered the interest in this bioactive lipid mediator. Five 
GPCR coupled receptors have been found to mediate the effects of S1P and 
stimulating various pathways; JNK, ERK (extracellular signal-regulated kinase), Rac, 
Rho, and PI3-kinase/Akt (Takabe, 2008). The first S1P analogue, fingolimod, is in 
clinical development and has been described earlier in this introduction. 
 
2.1.10  Disease as a consequence of dysregulated apoptosis 
Development of cancer is a multistep process that involves genetic alterations 
resulting in unlimited growth of cells. Prominent mechanisms of acquiring resistance 
to apoptosis include overactivation of anti-apoptotic proteins or mutation of pro-
apoptotic proteins. Examples of dysregulation of anti-apoptotic proteins include Bcl-2 
and Bcl-xL, IAPs, members of the PI3-kinase-Akt pathway and NFκB pathway. 
Inactivation of pro-apoptotic signals, on the other hand, is often caused by mutational 
changes of p53, Bax, and Apaf-1 and loss of expression of death receptors. The 
resistance of cancer cells to apoptosis hinders the success of cancer therapy and 
dependant of the kind of mutation therapy needs to be adjusted. Personalised cancer 
therapy seems the obvious strategy to pursue, as the type of mutation is fundamental 
for successful therapy.   
Cancer treatments that specifically target the altered apoptosis pathways are 
currently under development. Either by inhibition of the anti-apoptotic members or 
activation of pro-apoptotic pathways, cell death is stimulated in cancer cells. For 
example the earlier mentioned molecule gossypol, a BH3-mimicking inhibitor of Bcl-2 
and Bcl-xL. Inhibition by antisense nucleotide is another strategy, oblimersen, a Bcl-2 
antisense oligonucleotide is currently in phase III studies and could reach the market 
soon. Several agonist antibodies that target death receptors and induce apoptosis 
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 are in clinical studies phase I or II, for example mapatumumab and apomab. The 
proteasome inhibitor bortezomib (Velcade) blocks proteosomal degradation of 
proteins and activates caspase-8 and -9 in vivo, due to inhibition of the NFκB 
pathway. Velcade has been approved by the FDA in May 2003 for treatment of 
myeloma and has become the first anti-cancer drug on the market to target the 
proteasome and thereby, also the first to target NFκB activation (Folmer, 2008). 
In neurodegenerative disease the apoptotic pathways are altered in the other 
direction and too much apoptosis takes place (Jin, 2005). Neurons naturally possess 
very strong anti-apoptotic factors that help them to survive for the lifetime of the 
organism. In neurodegenerative diseases such as AD and Parkinson’s disease p53 
activation plays a critical role in cell death. The p53 inhibitor pifithrin was shown to 
inhibit in vitro amyloid peptide induced neuronal death and protect from neuronal loss 
in a Parkinson mouse model (Duan, 2002).  
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 2.2 PI3K/PIPs/Akt signalling pathway 
The serine/threonine kinase Akt, also known as protein kinase B (PKB), plays a 
central regulatory role in diverse cellular processes such as homeostasis, survival, 
cell cycle progression, and metabolism. Aberrant Akt signalling is observed in cancer 
development, insulin resistance and many other pathological conditions. As a general 
mechanism, activation of Akt is induced via surface receptor stimulation, where 
activated PI3-kinases catalyse the phosphorylation of membrane-bound 
phosphoinositides, thus creating docking sites for signalling proteins like Akt (Figure 
17). These signalling proteins coordinate complex events that lead to changes in cell 
metabolism, cell growth, cell movement and cell survival (Cantley, 2002). 
 
Figure 17: Diagram of the activation of Akt.(modified from www.cellsignaling.com)  
 
2.2.1 Akt pathway 
The Akt pathway is activated by receptor tyrosine kinases, B- and T-cell receptors, 
cytokine receptors, or G-protein-coupled receptors (GPCRs) that induce production 
of phosphatidylinositol-3,4,5-trisphosphates (PtdInsP3) by PI3-kinases 
(phosphoinositide 3-kinases). These lipids serve as membrane docking sites for 
proteins that harbour pleckstrin-homology (PH) domains, including Akt and its 
upstream activator PDK1, thereby recruiting them to the plasma membrane. PDK1 
phosphorylates Akt at Thr308, whereas the additional phosphorylation at Ser473 is 
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 accomplished by the mTOR complex 2 (TORC2) that further increases Akt activity 
(Huang and Manning, 2009). Once active, Akt regulates a number of downstream 
targets (Figure 18). Three mammalian isoforms of Akt have been identified, Akt1, 
Akt2, and Akt3. They share a high degree of structural similarity and more than 80% 
sequence homology. Each isoform plays an unique as well as a common role in cells 
(Parcellier, 2008).  
 
Figure 18: Effects of Akt activation on different cellular functions (Huang and Manning, 2009). 
 
Akt enhances the survival of cells by blocking the function of proapoptotic proteins 
such as inactivation of Bad, a BH3-only protein, by phosphorylation. This prevents 
binding of Bad to its target proteins Bcl-2 and Bcl-xL and hence promotes cell 
survival. Akt has also been reported to directly phosphorylate capsase-9 and thereby 
blocking its activation (Cardone, 1998). Furthermore Akt inhibits the transcription 
factor FoxO1 (forkhead box O1) that induces transcription of Bim, another BH3-only 
protein stimulating cell death. A further target of Akt that promotes cell survival is 
Mdm2, the negative regulator of p53, leading to translocation of Mdm2 into the 
nucleus where it inhibits p53 transcriptional activity (Figure 15).  
The impact of Akt on cell growth is mainly due to activation of the mTOR complex 1 
(TORC1), which is regulated by both nutrient and growth factor signalling. TORC1 
regulates protein synthesis by initiation of translation and biogenesis of ribosomes 
(Wullschleger, 2006). The enhanced sensitivity of cancer cells exhibiting oncogenic 
activation of the Akt-pathway to the mTOR inhibitor rapamycin, illustrates the 
importance of TORC1 activation downstream of Akt (Sabatini, 2006). 
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 Cell proliferation is stimulated by Akt through inhibitiory phosphorylation of the cyclin-
dependent kinase (CDK) inhibitors p21 and p27. Akt thus prevents translocation of 
p21 and p27 to the nucleus and attenuates their cell-cycle inhibitory effects (Liang 
and Richardson, 2003). Moreover, inhibitory phosphorylation of the glycogen 
synthase kinase 3 (GSK3) by Akt leads to cell cycle progression, as inactivation of 
GSK3 rescues β-catenin from degradation. β-catenin induces transcription of cyclin 
D1, which induces cell cycle progression (Osaki, 2004).  
Akt signalling also takes part in the regulation of nutrient uptake and metabolism. 
Upon stimulation with insulin, for instance, the glucose transporter Glut4, most likely 
through interaction with AS160 (Akt substrate of 160 kDa), translocates to the cellular 
membrane and enhances glucose uptake (Sano, 2003). Furthermore, the Akt-
mediated phosphorylation and inhibition of GSK3 stimulates glycogen synthesis.  
The Akt pathway interconnects with many other important pathways in the cell. 
Several studies have demonstrated that Akt signalling can activate NFκB upon a 
variety of stimuli, for instance upon stimulation with platelet-derived growth factor. 
Although there are likely to be multiple levels of crosstalk between Akt and NFκB, 
one mechanism consists in phosphorylation of IKK by Akt and subsequent activation 
of NFκB. Furthermore, activation of Akt influences other pathways such as ERK, 
JNK, and MAPK, as their pathways converge upstream.  
 
2.2.2 The phosphoinositide and phosphoinositide-kinases pathways 
Hokin and Hokin (1964) have first demonstrated phospholipid turnover in response to 
cell stimulation (Hokin and Hokin, 1964). Since then research in this field has yielded 
many mechanistic insights of phosphoinositide cell signalling.  
Phosphoinositides (PIs) are inositol-containing glycerophospholipids that can be 
reversely phosphorylated in several positions on the inositol ring (Figure 19). 
  
Figure 19: Structure of PIs 
The family of PIs consists of the mutual non-phosphorylated precursor 
phosphatidylinositol (PtdIns) and seven members with different phosphorylation 
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 patterns on the inositol ring, where the 3-, 4-, and 5- positions can be phosphorylated 
by specific kinases (Figure 20) (Wymann and Pirola, 1998). These phosphoinositide-
kinases (PI-kinases) are categorised into three families, depending on the position of 
the phosphorylation on the inositol ring: phosphoinositide 3-kinases (PI3-kinases), 
phosphoinositide 4-kinases (PI4-kinases or PIP4-kinases), and phosphoinositide 5-
kinases (PI5-kinases or PIP5-kinases).  
 
Figure 20: Interconversions of all the PIs, with indication of the respective enzyme and the disease 
resulting when proper function of the enzyme fails (figure from McCrea and De Camilli, 2009). 
 
2.2.3 Phosphoinositide-kinases 
The best characterised amongst them are the PI3-kinases that are further grouped 
into class I, II, and III, depending on their subunit structure, substrate specificity, and 
type of activation.  
PI3-kinases class I. The class I PI3-kinases are heterodimeric proteins that catalyse 
the formation of phosphatidylinositol-3,4,5-trisphosphate (PtdInsP3) from 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2). They all consist of a regulatory 
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 and a catalytic subunit and are subdivided into class IA, that contain the catalytic 
subunits p110α, β, or δ, and the class IB that contains the catalytic subunit p110γ 
(hence called PI3-kinase γ) (Vanhaesebroeck, 1997). The class IA PI3-kinases are 
downstream of receptor tyrosine kinases and can be activated by growth factor or 
insulin stimulation, cytokine signalling, or antibody binding, whereas the class IB is 
downstream of GPCRs and is activated by Gβγ subunits (Karataeva and Nevinsky, 
2007). Although the two classes couple to different surface receptor systems, they 
share the small GTPase Ras as an interacting partner (Wymann and Pirola, 1998).  
PI3-kinases class II. Class II PI3-kinases are monomers of relatively large molecular 
mass (170-220 kDa) and comprise three catalytic isoforms (C2α, C2β, and C2γ). 
Unlike class I and III, class II contains no regulatory protein. They mainly catalyse the 
production of PtdIns3P from PtdIns and PtdIns(3,4)P2 from PtdIns4P (Falasca and 
Maffucci, 2007; McCrea and De Camilli, 2009).   
PI3-kinase class III. Class III PI3-kinases have a substrate specificity restricted to 
PtdIns. These PI3-kinases are homologous to Vps34 (vacuolar protein sorting 34), 
the only PI3-kinase in yeast. Vps34 is closely associated with Vps15, which has been 
described as a Vps34 regulatory subunit and was therefore named p150 in 
mammals, analogous to the class I regulatory subunits (Backer, 2008; 
Vanhaesebroeck, 1997).   
PI4-kinases. Two types of PtdIns 4-kinase have been identified. One that only 
catalyses PtdIns to PtdIns4P, called PI4-kinase, and one that catalyses PtdInsPs to 
PtdIns(3,4)P2 or PtdIns(4,5)P2, respectively, called PIP4-kinase (Jones, 2000; Rusten 
and Stenmark, 2006).   
PI5-kinases. There are two types of PI5-kinase. A characteristic feature is that they 
only phosphorylate PtdInsPs to PtdInsP2. PIKfyve converts PtdIns3P to 
PtdIns(3,5)P2, while PIP5-kinase phospohorylates PtdIns4P to PtdIns(4,5)P2 (Krauss 
and Haucke, 2007). To date no PI5-kinase is known that phosphorylates PtdIns to 
PtdIns5P. 
In summary, the PI3-kinases have been well investigated, but little is known about 
the other PI-kinases. Studies on PI4- and PI5-kinases are few and their biological 
significance not fully understood. 
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Figure 21: Localisation of the specific PtdIns at different membranes in the cell (figure from McCrea 
and De Camilli, 2009). 
 
2.2.4 Roles of the different phosphoinositides 
PtdIns is the most abundant PI and together with PtdIns4P and PtdIns(4,5)P2 they 
build the so called canonical pathway. These PIs are kept at constant levels at the 
plasma membrane, whereas the other PIs are considered to be low-abundant 
signalling molecules that transiently appear upon specific stimulation. Furthermore 
PtdIns(4,5)P2 serves as precursor of the intracellular second messengers DAG and 
inositol-(1,4,5)-trisphosphate (IP3), that are formed through phospholipase C (PLC) 
mediated hydrolysis of PtdIns(4,5)P2. DAG binds and regulates protein kinase C 
(PKC) and a variety of other effectors, whereas IP3 triggers calcium release from the 
endoplasmic reticulum. PtdIns(4,5)P2 can also be cleaved by phospholipase A2 
(PLA2) to generate arachidonic acid, the precursor of inflammatory eicosanoids 
(McCrea and De Camilli, 2009). 
 
PtdInsP3. The generation of PtdInsP3 stimulates numerous signalling pathways that 
are involved in cell proliferation, metabolism, motility and immune responses. 
PtdInsP3 recruits PH domain-containing proteins such as Akt, PDK1, PLC, BKT 
(bruton’s tyrosine kinase), and GTPases-activating factors, to the membrane where 
they build signalling complexes to produce a specific signal in the cell (Sasaki, 2007). 
More than 250 proteins in humans have been found to contain a PH binding domain 
and are therefore potential binding partners of PtdInsP3. However, the most 
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 important effector is Akt. ‘Not all PI3-kinase signalling is mediated via Akt, but clearly 
a major part of it’ (Downward, 2004). PtdInsP3 levels resulting after activation of PI3-
kinses class I are tightly regulated by the action of phosphatases such as PTEN 
(phosphatase and tensin homologue deleted on chromosome ten) and SHIP (SH2-
containing inositol 5-phosphatase) that dephosphorylate PtdInsP3 to PtdIns(3,4)P2 
and PtdIns(4,5)P2, respectively (Figure 20). Deregulated PtdInsP3 signalling is tightly 
associated with tumour development, either through mutational changes in receptors 
that result in constant activation of PI3-kinases or by mutational changes of PTEN 
and hence impaired shut-down of the signal.  
 
PtdInsP2. The bisphosphorylated PIs, PtdIns(3,4)P2, PtdIns(3,5)P2, and PtdIns(4,5)P2  
have distinct functions in cell signalling. PtdIns(3,4)P2 is responsible for signal-
extension after PtdInsP3 induction since some of the PtdInsP3 binding proteins also 
recognise PtdIns(3,4)P2, namely PDK1 and Akt. The 5-phosphtase SHIP, 
responsible for dephosphorylation of PtdInsP3 to PtdIns(3,4)P2 has important roles in 
cells of the immune system and in blood platelets (Blero, 2007). SHIP1 deficient mice 
display overactive immune responses and platelet clotting. SHIP2 is important for 
control of insulin sensitivity (Sasaoka, 2006).   
PtdIns(3,5)P2 has a role in membrane and protein trafficking (Figure 21) and is 
believed to be only produced via PtdIns3P and subsequent 5-phosphrylation (Michell, 
Lemmon, Dove, 2006). Besides its function as a precursor of PtdInsP3, DAG, and 
IP3, PtdIns(4,5)P2  has some specific functions in regulation of the actin cytoskeleton, 
exo- and endocytoic processes. PtdIns(4,5)P2 is associated with small GTPases and 
participates in recruitment and activation of a wide variety of regulatory proteins (Di 
Paolo and De Camilli, 2006).  
 
PtdInsP. The phosphoinositide monophosphates were long thought to be mere 
intermediate metabolites in the pathway. In yeast the only PI3-kinase Vps34 is 
responsible for the production of PtdIns3P and plays a critical role in the sorting of 
proteins from the golgi to the vacuole (Pendaries, 2005). In mammals it is involved in 
vesicular trafficking (Wurmser, 1999). Besides being an intermediate product on the 
way to PtdIns(4,5)P2, PtdIns4P is enriched at the Golgi membrane and targets Golgi-
associated proteins (Figure 21) (Pendaries, 2005). The role of PtdIns5P as signalling 
molecule just emerges, as it is the most recently discovered inositol lipid (Rameh, 
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 1997). It was shown that PtdIns5P levels rise upon thrombin stimulation in platelets 
(Morris, 2000) and during osmotic stress in mammalian cells (Sbrissa, 2002). 
 
2.2.5 PI3-kinase/Akt signalling in disease 
PI3-kinases were originally discovered because of their association with viral 
oncoproteins (Cantley, 1991) and increased PI3-kinase signalling has since then 
been found in many cancers. Abberant PI3-kinase/Akt activation occurs in cancer 
through a variety of mechanisms. These include mutations or amplification of 
upstream regulators such as receptors and PI3-kinases, inactivation of PTEN, or 
amplification of Akt. Mutational activation of PI3-kinase IA is found in 15% of all 
tumour types, suggesting that this may be the most commonly mutated kinase 
(Crabbe, 2007). The PTEN gene is commonly inactivated in cancer cells and is the 
second most mutated tumour suppressor gene after p53 (Trotman and Pandolfi, 
2003). Another negative regulator of PtdInsP3 is SHIP, and the isoform SHIP2 has 
been implicated in development of diabetes. SHIP2 is responsible for the control of 
the cellular response to insulin. Elevated levels of SHIP2 expression are found in 
cells that show insulin resistance.  
A role of PtdIns(4,5)P2 in the early onset of Alzheimer’s Disease in Down Syndrome 
has been suggested (Voronov, 2008). Synaptojanin I, a PtdIns(4,5,)P2 phosphatase 
plays a critical role in synaptic transmission and is located in the chromosome 21 
region that is triplicated in Down Syndrome. Accordingly levels of synaptojanin I are 
increased and might add to the early development of AD (McCrea and De Camilli, 
2009). Furthermore some hereditary diseases were linked with genetic defects in the 
PI-signalling system (Figure 20). Lowe syndrome is a X-linked condition that results 
in severe mental retardation, growth defects, and eye defects. It is caused by 
mutations in the inositol-5-phosphatase OCRL (occulocerebrorenal syndrome of 
Lowe) that dephosphrylates PtdIns(4,5)P2 to PtdIns4P. The cellular causes of the 
varied disease phenotypes are not yet understood (Skwarek and Boulianne, 2009). 
Another disease cause by impaired PI metabolism is Charcot-Marie-Tooth (CMT) 
disease that affects peripheral nerves and is the most common inherited neurological 
disorder. Several different subtypes of CMT disease are due to mutations in lipid 
phosphatases involved in dephosphorylation of PtdIns(3,5)P2 at either the 3- or 5- 
position (Robinson, 2008). 
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 Targeting of the PI3-kinase pathway is aimed at since the important role of this 
pathway has been recognised. Various molecules are in clinical development, the Akt 
inhibitor perifosine, PI3-kinase inhibitors, and already in clinical use, the mTOR 
inhibitor rapamycin (Yap, 2008). Unfortunately selective inhibition of the PI3-kinases 
has not been achieved yet. The non-selective PI3-kinase inhibitor wortmannin and its 
role as a model substance in molecular biology were discussed in chapter 1.5.2. 
Selective inhibitors of PI3-kinase gamma were once thought to become the ‘aspirine 
of the 21st century’ (Ruckle, 2006) but no sufficiently selective inhibitor has been 
found yet to fulfil that prophecy.  
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 3 Aim of the thesis 
 
The importance of natural products as sources of inspiration for drug discovery and 
development and as tools for basic research is undisputed. The combination of 
traditional knowledge and modern scientific research has been a successful strategy 
to identify new active substances that might serve as lead structures for drug 
discovery, and natural products have offered numerous opportunities to study 
unknown cellular mechanisms.  
The exploitation of natural products is limited by the fact that the modes of action of 
numerous compounds are poorly understood. The potential of a given compound can 
only be assessed if sufficient information is available regarding their molecular 
targets. The natural products analysed during this thesis have both some background 
in traditional medicine and have been identified with the aid of functional assays. In 
order to assign these observed effects to an interaction on the molecular level, we 
studied associated signal transduction pathways in cells, namely: 
(i) Phosphorylation of proteins  
(ii) Activation of transcription factors 
(iii) Concentration of second messengers (i.e. phosphoinositides) 
(iv) Localisation of the substance within the cell 
 
In the first part of this thesis the molecular effects of the fungal alkaloid militarinone A 
were studied. In an earlier screening for neurotrophic substances, the extract of the 
entomogenous fungus Paecilomyces militaris had been shown to induce increased 
spike formation in PC12 cells (Schmidt, 2003), and militarinone A had been 
subsequent identified as the active metabolite via activity guided fractionation (Figure 
22) (Schmidt, 2002).  
 
Figure 22: Structure of militarinone A. 
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 To uncover the mechanism of this activity we studied the cell signalling pathways 
involved in neuronal spike formation and differentiation in two types of neuronal cells 
(PC12 and N2a) and the interaction of militarinone A with associated pathways. 
 
In the second part, an alkaloid from the traditional European medicinal plant woad 
was analysed. Woad (Isatis tinctoria) contains several known anti-inflammatory 
components, namely, tryptanthrin, indirubin, and (E,Z)-3-(3’,5’-dimethoxy-4’-hydroxy-
benzylidene)-2-indolinone (indolinone (Figure 23)). The effects of tryptanthrin as a 
potent inhibitor of COX-2 (Danz, 2002), 5-LOX (Oberthur, 2005), and of nitric oxide 
production catalyzed by inducible NO synthase (iNOS) (Ishihara, 2000) are well 
characterised and account for a good part of the anti-inflammatory activity of the 
plant extract. Indirubin is used in Chinese medicine (from isatis indigotica) as an anti-
leukemia treatment and has been shown to inhibit cyclin-dependent-kinase 2 (CDK2) 
(Hoessel, 1999) while indolinone was shown to inhibit degranulation of mast cells 
(Rüster, 2004).  
   
Figure 23: Structure of indolinone. 
The anti-allergic activity of indolinone should be further characterised. Given the 
structural similarities with indolin-2-one derived kinase inhibitors, we focussed on 
signalling pathways associated with degranulation to determine the mechanism and 
point of action of indolinone.  
 
During the studies on indolinone, measurements of intracellular PtdInsP3 (Figure 19) 
were initially performed with the current standard methodology that includes 
radioactive labelling with 32Pi, ion-exchange HPLC and flow scintillation analysis 
(Dove, 1997; Laffargue, 2002). The method proved to be laborious, time-consuming 
and potentially hazardous. This led us to develop a non-radioactive method for 
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 analysis of phosphoinositides based on chromatographic separation and mass 
spectrometry detection. This method would allow analysis of all phosphoinositides 
without the need for radioactive labelling and should be of interest for many other 
laboratories, as it offers new perspectives in detection and relative quantification of 
phosphoinositides. 
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 B.    PUBLICATIONS 
 
˝It’s a wild dance floor there at the molecular level˝ 
- Roald Hoffmann in ‘Designing the molecular world’ by Philip Ball (p.83)  
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Abstract The fungal alkaloid militarinone A (MiliA) was
recently found to stimulate neuronal outgrowth in PC-12
cells by persistant activation of pathways that are also
involved in NGF-mediated differentiation, namely the PI3-
K/PKB and the MEK/ERK pathways. Application of equal
concentrations of MiliA to other cells such as the murine
neuroblastoma cell line N2a resulted in immediate onset of
apoptosis by nuclear translocation of apoptosis inducing
factor (AIF), activation of caspases and c-Jun/AP-1 tran-
scription factor without an intermediate differentiated
phenotype, although minor transient phosphorylation of
PKB and MAPK as well as activation of NF-jB were also
observed. Translocation of AIF was preceded by p53
phosphorylation at Ser15 and blocked by pifithrin a, a
known inhibitor of p53-transcriptional activity. We here
show that both cell types activate the same pathways albeit
in different time scales. This is mainly due to contrasting
basal expression levels of p53, which in turn regulates
expression of AIF. In PC-12 cells, continuous activation of
these pathways after prolonged treatment with 40 lM
MiliA first led to up-regulation of p53, phosphorylation of
p53, release of AIF from mitochondria and its translocation
into the nucleus. Additionally, also activation of the c-Jun/
AP-1 transcription factor was observed, and PC-12 cells
subsequently underwent apoptosis 48–72 h post-treatment.
We report that similar pathways working on different
levels are able to initially shape very divergent cellular
responses.
Keywords Neurite extension  Apoptosis  p53 
AIF  Natural products
Introduction
Neurotrophic factors are capable of preventing apoptosis in
neuronal cells, and exogenous supplementation with such
factors have been proposed as a new disease-modifying
strategy in the treatment of neurogenerative diseases.
However, clinical trials have been disappointing so far due
to difficulties in delivery of these glycoproteins into the
central nervous system [1]. Small non-peptidic molecules
with neurotrophic properties, and capable of penetrating
the blood–brain barrier, have been proposed as an alter-
native [2]. In the course of a screening for such molecules
we discovered that the fungal alkaloid militarinone A
(MiliA) induced neurite extension in PC-12 cells [3]. Due
to its amphiphilic properties MiliA was rapidly integrated
into the membranous fraction where it triggered PI3-K/
PKB- and ERK1/2-dependent differentiation [4, 5]. PKB
promotes survival of a variety of neuronal cells and has
been shown to be required for neuronal outgrowth [6, 7]. In
addition, phosphorylation and activation of the MAPKs
ERK1/2 [8] have also been connected with neuronal
differentiation [9], albeit its function is not fully clear.
Apoptosis inducing factor (AIF) is a mitochondrial
flavoprotein that is mainly located in the mitochondrial
intermembrane space. In healthy cells, AIF is required for
efficient oxidative phosphorylation. Upon apoptotic insult,
it translocates to the cytosol and subsequently into the
nucleus where it eventually binds to DNA and induces
caspase-independent cell death [10–12]. The concept that
AIF is able to induce apoptotic cell death independent of
caspases is supported by a series of experiments where
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programmed cell death was executed even in presence of
chemical caspase inhibitors such as Z-VAD-Fmk (zVAD)
or BAF. Moreover, AIF translocation was also observed in
mice in the absence of caspase activation [13], and the
biochemical changes were consistent with those described
in many caspase-dependent cell death models [14]. Con-
trasting with its death-inducing properties after nuclear
translocation, mitochondria-located AIF has been shown to
have a protective role in healthy and in tumour cells [11,
15]. Mitochondrial AIF is even thought to contribute to cell
survival by protecting cells against harmful oxidative
damage in the absence of deleterious stress while predis-
posing them to a more efficient killing in response to severe
stress. Recently, it has been reported that the aif gene is a
transcriptional target of basal levels of p53 [16].
p53 is a key tumour suppressor protein that is stabilised
and phosphorylated due to genotoxic stress and is nega-
tively controlled by Mdm2 which in turn is positively
controlled by PI3-K-PKB signalling [17, 18]. Once acti-
vated, p53 is able to promote cell-cycle arrest, apoptosis,
differentiation, senescence or DNA repair [19, 20]. It may
translocate to the nucleus where it regulates a plethora of
genes eventually leading to the expression of Bax, Bid, FAS
and redox-related genes. Therefore, a model was proposed
in which p53 initiates apoptosis through the regulation or
generation of reactive oxygen species (ROS) [21].
ROS are by-products of aerobic oxidation, mediate
toxicity but also work as signalling molecules [22]. Among
others, ROS activate diverse transcription factors such as
AP-1, antioxidant responsive element (ARE) and NF-jB
[23–25]. AP-1 describes a group of related members of the
Jun/Fos family and is involved in various cellular processes
depending on the composition of AP-1 dimers and on the
cell type. It is commonly thought that in neuronal cells,
c-jun has pro-apoptotic function [26], but a simple increase
of c-jun concentration was considered to be insufficient to
efficiently trigger neuronal cell death [27]. The contribu-
tion of AP-1 to survival, apoptosis or differentiation is
strictly depending on the cellular situation at a given time
point. ARE is important for cell defence under conditions
of oxidative stress [24], and NF-jB is a multifunctional
transcription factor mainly involved in promoting cell
survival [28].
Decline of mitochondrial integrity is considered to be of
major importance in generation of oxidative stress and
induction of apoptosis through the release of AIF and
cytochrome c [14, 29]. It is widely accepted that Bcl-2
proteins such as Bax or Bad are able to disturb the outer
mitochondrial membrane leading to the release of these
small molecules, and that other Bcl-2 proteins such as
Bcl-xL or Bcl-2 itself are capable to prevent this.
We report here that the small non-peptidic molecule
MiliA is capable of inducing signalling complexes such as
PI3-K/PKB, MEK/ERK, p53 and accumulation of ROS
that together contribute to neurite extension or/and apop-
tosis depending on the basal expressional level of p53.
Materials and methods
General remark
All experiments have been successfully reproduced at least
three times.
Materials and cell culture
Rat PC-12 cells were a kind gift from Prof. Anne Eckert
(Neurobiology Research Laboratory, University Clinic for
Psychiatry, Basel, Switzerland). Cells were maintained in
Dulbecco’s modified Eagle medium (DMEM; Sigma-
Aldrich, Buchs, Switzerland) supplemented with 5%
heat-inactivated foetal calf serum (FCS, Amimed, Basel,
Switzerland), 10% heat-inactivated horse serum (Amimed,
Basel, Switzerland), 100 U/ml penicillin/streptomycin
(Invitrogen, Basel, Switzerland), and 2 mM L-glutamine
(Invitrogen, Basel, Switzerland). Murine Neuro 2a (N2a)
cells were maintained in DMEM supplemented with 10%
FCS, 100 U/ml penicillin/streptomycin and 2 mM L-glu-
tamine. Both cell types were grown in humified atmosphere
containing 5% CO2. PC-12 cells stably overexpressing
TrkA were a kind gift from Prof. Frank-D. Bo¨hmer,
(Institute of Molecular Cell Biology, Jena, Germany) and
were treated as described [3]. The following chemicals
have been used: LY294.002, zVAD, pifithrin a (PFTa) (all
from Alexis Corporation, Lausen, Switzerland); N-Acetyl-
L-cysteine (NAC) and nerve growth factor (NGF) (both
from Sigma-Aldrich, Buchs, Switzerland). All chemical
inhibitors were added 30 min prior to stimulation.
Western blot
Immunoblot analysis was performed according to standard
procedures essentially as described [30]. Nitrocellulose
membranes were blocked and incubated overnight at 4°C
with specific primary Ab diluted in blocking buffer (5%
BSA in TBS-Tween): anti-PKB 1:1000; anti-Phospho-PKB
(Ser473) 1:1000; anti-ERK1/2 1:2000; anti-Phospho-
ERK1/2 (Thr202/Tyr204) 1:1000; anti-AIF 1:2000; anti-
Phospho-p53 (Ser15) 1:2000 (all rabbit polyclonal); mouse
monoclonal anti-p53 1:1000 (all Cell Signaling Technol-
ogy, Beverly, MA, USA); goat polyclonal anti-Actin
1:4000 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Specific bands were tagged using specific, HRP conjugated
secondary Abs and detected using the ECL Plus System
(GE Healthcare, Little Chalfont, UK).
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Immunofluorescence microscopy and light microscopy
PC-12 and N2a cells were fixed in 4% formaldehyde in PBS
for a minimal 15 min at 4°C, permabilised with 0.2% Tri-
ton-X (prepared in PBS containing 10% heat-inactivated
FCS) and then incubated with primary Ab. The Abs were
diluted in PBS containing 10% heat-inactivated FCS and
used at the following conditions: rabbit polyclonal anti-AIF
(diluted 1:50), rabbit anti-Phospho-p53 (Ser15) (diluted
1:100), mouse monoclonal anti-p53 (diluted 1:200) (all
from Cell Signaling CST). Subsequently the cells were
washed thrice with PBS and incubated for 1 h with affinity-
purified Alexa-Fluor 488 goat anti-rabbit IgG (H + L) or
Alexa-Fluor 488 goat anti-mouse IgG (H + L) (both from
Invitrogen-Molecular Probes, Basel, Switzerland), respec-
tively. Nuclei were counterstained with Dapi (diluted
1:4000 in PBS) (from Invitrogen-Molecular Probes, Basel,
Switzerland). Cells plated on coverslips were mounted on
glass slides and visualised by confocal microscopy (Leica
DM RXE scanning confocal microscope) using Leica
confocal software, version 2.5 (Leica Microsystems,
Heidelberg, Germany) or on a fluorescence microscope
(Axiophot, Carl Zeiss AG, Jena, Germany) using the anal-
ySIS Software (Soft Imaging Systems, Mu¨nster, Germany).
Identical exposure times were used across conditions.
Light microscopy pictures were taken on a Leitz
Laborlux (Ernst Leitz, Wetzlar, Germany) equipped with a
Leica DC200 Camera (Leitz Microsystems AG, Glattbrugg,
Switzerland) and analysed with Leica DC Viewer Software
version 3,2,0,0 (Leica Microsystems AG, Heerbrugg,
Switzerland).
Flow cytometry and measurement of membrane
potential
To detect caspase activation, staining with FITC-valyl-
alanyl-aspartic acid fluoromethyl ketone (FITC-VAD-fmk;
Promega) was carried out as described [30]. Annexin V
staining of exposed membrane phosphatidylserine was
carried out using the Annexin V assay kit (Roche
Diagnostics, Rotkreuz, Switzerland) following the manu-
facturer’s protocol. Quantification of loss of membrane
potential was determined by incubating 1 9 106 cells with
2 nM DiOC6(3) in serum-reduced media at 37°C for
30 min. After start of treatment, aliquots were taken at time
points indicated, diluted in PBS and subjected to flow
cytometry. FACS Analysis was performed on a Dako
CyAn
TM
ADP LX 7 using Summit software (DakoCyto-
mation, Fort Collins, CO, USA).
Measurement of intracellular ROS
The accumulation of ROS in PC-12 and N2a cells was
determined by analysis of dichlorofluorescein fluorescence.
Cells were plated in serum-containing DMEM into 96-well
plates and allowed to adhere overnight at 37°C. After
washing twice with PBS, 2,7-dichlorofluorescein diacetate
(DCFH-DA; Invitrogen-Molecular Probes, Basel, Switzer-
land) was applied at 10 lM in PBS for 45 min at 37°C.
After removal of the supernatant, cells were re-suspended
in serum-containing DMEM including drugs or vehicle
only and incubated for 60 min at 37°C. DCF fluorescence
was quantified (excitation: 492 nm; emission: 535 nm)
using a Chameleon microplate reader (Hidex Oy, Turku,
Finland).
Alternatively, cells were left to grow on coverslips and
subsequently loaded with 5 lM DCFH-DA for 30 min.
After incubation with drugs in serum-containing DMEM,
the cells were fixed with MeOH at -20°C for 5 min and
analysed by immunofluorescence microscopy as described
above. Identical exposure times were used across
conditions.
Preparation of nuclear extracts, electrophoretic mobility
shift assay and supershift
Cells were collected and washed with ice-cold PBS (pH 7.4)
and lysed in a hypotonic buffer (10 mM Hepes, pH 7.9,
60 mM KCl, 1 mM EDTA, 1 mM DTT, 0.5% NP-40) con-
taining protease inhibitors (1 mM PMSF, 19 CompleteÒ
Protease Inhibitors (Roche Diagnostics, Rotkreuz, Switzer-
land)). The nuclei were collected by centrifugation at 800g
for 5 min at 4°C and washed once in ice-cold hypotonic
buffer without NP-40. Nuclei were subsequently re-sus-
pended in nuclear buffer (250 mM Tris–HCl, pH 7.8,
60 mM KCl, 1 mM EDTA, 1 mM DTT, 0.5% NP-40) con-
taining protease inhibitors (1 mM PMSF, 19 CompleteÒ
Protease Inhibitors). Nuclear membranes were disrupted by
freeze-thawing followed by centrifugation at 13,200g for
30 min. The supernatant (nuclear extract) was collected and
the protein concentration was measured using CoomassieÒ
Protein Assay Reagent (Sigma-Aldrich, Buchs, Switzer-
land). The binding reactions were carried out as described
[31]. Briefly, nuclear extracts containing 3 lg nuclear pro-
teins were incubated for 20 min with 32P-radiolabelled
oligonucleotides in 20 ll reaction buffer. For supershift
analysis, 1 lg of anti-c-jun (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) was added and incubated on ice for
another 30 min. Nuclear protein-oligonucleotide and anti-
body-protein-oligonucleotide complexes, respectively, were
resolved by electrophoresis on a 4% non-denaturing poly-
acrylamide gel in 0.259 TBE buffer at 20 V/cm for 35 min
at room temperature. The gel was dried and autoradio-
graphed on an intensifying screen at -80°C. Double
stranded, palindromic oligonucleotides containing the con-
sensus sequences for ARE (50-AAA TGG CAT TGC TAA
TGG TGA CAA AGC AAC T-30) [32], NF-jB (50-AGT
366 Apoptosis (2008) 13:364–376
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TGA GGG GAC TTT CCC AGG C-30) [31] or AP-1
(50-GAATCGAGCATGAGTCAGACACA-30) [33]were
used.
Results
We previously reported [3] that addition of 40 lMMiliA to
PC-12 cells for 24 h after pre-treatment with NGF [34]
induced neurite outgrowth which was attributed to the NGF-
dependent up-regulation of its receptor TrkA. However, pre-
treatment with a commercially available TrkA-inhibitor that
was able to prevent NGF-induced phosphorylation of PKB
and MAPKs, did not prevent MiliA-dependent phosphory-
lation of these proteins (Fig. 1a) and suggested that
phosphorylation of TrkAwas not involved inMiliA-induced
neurite extension. When applying 40 lM MiliA to PC-12
cells stably over-expressing TrkA (TA) and naı¨ve PC-12, we
observed similar neuronal outgrowth in both cases (Fig. 1
and [3]. In addition, phosphorylation of PKB andMAPKs in
TA (not shown) and naı¨ve PC-12 was found (Fig. 1c).
Since up-regulation of the PKB and MAPK-pathways
was independent of TrkA, we wanted to know if MiliA-
induced phosphorylation of these signalling molecules
occurred also in other neuronal cell-lines. Treatment of
N2a cells with 40 lM MiliA led to a down-regulation of
the endogenous PKB and MAPK phosphorylation (Fig. 1
e). This was accompanied by a marked loss of protein
content from samples treated with MiliA compared to
vehicle-treated controls (not shown). Moreover, light
microscopy revealed that most of the cells had lost
adherence, were oddly shaped or had crumbled (Fig. 1d).
To discriminate between necrotic and apoptotic cell
death, we double-stained N2a cells treated with 40 lM
MiliA or vehicle only with Annexin V/PI. The over-
whelming part of cell death observed was due to apoptotic
mechanisms (Fig. 2a) becoming evident as early as 2 h
post-treatment. Additionally, chromatin condensation
Fig. 1 40 lM MiliA induced
TrkA-independent neurite
extension in PC-12, but
immediate apoptosis in N2a
cells. (a) Inhibition of TrkA
blocked NGF-dependent but not
MiliA-dependent
phophorylation of PKB and
ERk1/2. (b) PC-12 cells stably
transfected with TrkA (left
panels) and naı¨ve PC-12 (right
panels) showed similar neuronal
outgrowth after 24-h treatment
with MiliA. (c) Phosphorylation
of PKB (Ser473) and MAPKs
(ERK1/2; Thr202/Tyr204) was
clearly detected after 24 h in
PC-12 cells. (d) N2a cells lost
adherence and normal shape
upon addition of MiliA and (e)
no additional phosphorylation
of PKB (Ser473) nor MAPKs
(Thr202/Tyr204) could be
detected after 24 h
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occurred in cells treated with MiliA for 8 h or longer
(Fig. 2b), as visualised in N2a cells stained with Dapi. To
test if caspases were involved in the execution of the cel-
lular death observed, MiliA-treated N2a cells were stained
with the FITC tagged form of the general caspase inhibitor
zVAD and submitted to FACS-analysis: A distinct popu-
lation showing activation of caspases roughly doubled from
26.6 to 60% 24 h post-treatment (Fig. 2c). We tested in a
next step whether pre-treatment with zVAD (20 lM)
would be able to suppress onset of apoptosis, but addition
of zVAD only slightly diminished the extent of Annexin
V-positive cells by -2.3 ± 8.7% (data calculated from six
independent experiments), and a complete inhibition was
never observed after 3 h of treatment with 40 lM MiliA
(Fig. 2d). Besides, co-incubation of N2a cells with zVAD
and MiliA did not slow the progress of apoptosis, and a
phenotype showing neurite extension was observed neither
in absence nor in presence of zVAD. As caspase-inde-
pendent pathways could in addition be activated by
administration of MiliA, we checked for nuclear translo-
cation of AIF, a protein normally residing in the
mitochondrial intermembrane space [10]. In N2a cells, AIF
translocation was detected by confocal immunofluores-
cence microscopy as early as 4–6 h post-treatment
(Fig. 2e). When we checked for simultaneous release of
cytochrome c, another pro-apoptotic mitochondrial protein
[35], we failed to detect any significant change in locali-
sation (not shown). These findings suggested a specific
release of AIF.
As PC-12 showed neurite extension 1 day after addition
of 40 lM MiliA, we investigated the effect of prolonged
MiliA-treatment on PC-12 cells. Treatment for 1 day only
slightly elevated the quantity of Annexin V-positive and
Annexin V/PI double-positive cells, but these numbers were
substantially increasing after 3 days (Fig. 3a). However,
also PI-positive cells were observed and suggested addi-
tional necrotic mechanisms. Next we looked for caspase-
activation using FACS-analysis of FITC-VAD-Fmk-stained
cells but failed to detect any activation 1 day post-treatment
(Fig. 3b). Even after 2 days post-treatment, no activation
was observed (not shown). However, most of cells showed
clear nuclear translocation of AIF between 2 and 3 days
post-treatment (Fig. 3c) and analogous to the situation in
N2a cells, no significant change in cytochrome c localisa-
tion could be detected.
Militarinone A has been reported to rapidly integrate
into the membranous fraction [3] due to its amphiphilic
properties [36], whereas release into the cytoplasm was
markedly slower. As both PC-12 and N2a cells showed
release of AIF, we isolated whole, viable mitochondria
Fig. 2 Treatment with 40 lM
MiliA led to caspase-dependent
as well as -independent
apoptosis in N2a cells. (a) Early
signs of apoptosis by binding of
Annexin V to the cell surface
were detected as early as 2 h
after treatment with MiliA
(40 lM). (b) Late signs for
programmed cell death such as
chromatin condensation were
observed in cultures treated with
40 lM MiliA for 24 h. (c)
General activation of caspases
was detected by FACS analysis
of FITC-VAD-Fmk-stained
cells after 24 h. (d) Co-
treatment with the general
caspase inhibitor zVAD
(20 lM) led to only a marginal
reduction of programmed cell
death after 3 h as shown by
Annexin V/PI staining. (e)
Release and nuclear
translocation of AIF was
observed in cells treated for 4 h
or longer, as shown by confocal
immunofluorescence analysis
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from both cell lines to check for membranal integration of
MiliA. This rapidly occurred between 30 and 120 s after
addition of the compound and was indistinguishable from
integration into the cellular membrane (not shown) in both
cell types. This observation was unexpected given that N2a
showed release of AIF and early apoptosis whereas PC-12
displayed neurite outgrowth and a late onset of cell death.
As loss of membrane potential is a sign for the de-stabili-
sation of mitochondria and a pre-requirement for AIF-
release [37], we expected to see a rapid depolarisation in
N2a, and a significantly slower effect in PC-12. Loss of
membrane potential, however, took place at comparable
speed in both cell lines (Fig. 4a). We therefore postulated
that PC-12 cells would notwithstanding be less prone to the
release of ROS from mitochondria due to loss of membrane
potential and we visualised the occurrence of ROS-derived
oxidation by measurement of DCF fluorescence via
immunofluorescence microscopy. But again, both cell lines
reacted in a similar manner to the administration of MiliA
(Fig. 4b). When we quantitatively measured the production
of ROS we found no significant difference between PC-12
and N2a cells (Fig. 4c). Moreover, the production of ROS
by 40 lM MiliA was comparable to administration of
100 lM H2O2 and could be efficiently blocked by addition
of 15 mM NAC. Given the fact that between depolarisation
of the mitochondria and release of ROS, respectively, and
induction of cellular death passed several hours (N2a) or
even 1–3 days (PC-12), we assume that the release of ROS
resulted in activation of signalling pathways not directly
involved in apoptosis, as suggested by other publications
[38].
To test the involvement of ROS-production in the
propagation of apoptosis and neurite extension, respec-
tively, we co-treated both cell-lines with 40 lM MiliA and
15 mM NAC. PC-12 cells remained unaffected (not
shown) and N2a cells showed an apoptotic phenotype
indistinguishable from MiliA-only treated cells (Fig. 4d).
Even though NAC blocked accumulation of ROS (Fig. 4c),
the compound did not rescue N2a cells from cell death.
Neither loss of membrane potential nor increase of
ROS-levels sufficiently explained the marked difference in
reaction of PC-12 and N2a cells to MiliA treatment.
Therefore we tested for DNA-binding activities of tran-
scription factors that are reportedly activated by ROS, and
bind to consensus sequences of ARE, NF-jB and AP-1
[23–25]. ARE activity raised rapidly and transiently in N2a
and PC-12 after addition of MiliA, reaching its peak after
1 h (Fig. 5a) as shown by electrophoretic mobility shift
assay (EMSA). DNA-binding activity of AP-1 (Fig. 5b)
and NF-jB (Fig. 5c), on the other hand, were differentially
regulated in the two cell lines. N2a showed rapid induction
of NF-jB and AP-1-binding, peaking between 2 and 4 h.
Thereafter, no further activity could be detected. In PC-12
cells, binding of these two transcription factors was more
pronounced but only observed from 24–48 h post-
treatment.
To test if AP-1 and NF-jB were activated by ROS, we
incubated N2a and PC-12 cells pre-treated with 15 mM
NAC with MiliA for 4 and 24 h, respectively, and per-
formed EMSA. Only the NF-jB DNA-binding activity was
successfully inhibited by NAC in both cell lines (Fig. 5d),
whereas AP-1 remained unaffected (not shown). These
experiments suggested that ROS would not directly be
involved in MiliA-dependent apoptosis but could contrib-
ute to initial survival mechanisms mainly through NF-jB
activation.
p53 plays an important role in the management of
intracellular stress and regulates basal levels of AIF [16].
Fig. 3 PC-12 cells undergo homologous apoptosis as N2a cells upon
prolonged treatment with 40 lM MiliA. (a) Early signs for apoptosis
were detected after 1 day and became more pronounced after 3 days,
as shown by binding of Annexin V to the cell surface and FACS
Analysis in PC-12 cells. (b) General activation of caspases was not
detected by FACS analysis of FITC-VAD-Fmk stained cells after
1 day. (c) Translocation of AIF (green) into the nucleus (blue) in PC-
12 cells after a 3 day-treatment with MiliA (40 lM)
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Fig. 4 Immediate loss of membrane potential and release of ROS
were detected in both cell lines after addition of 40 lM MiliA. (a)
Loss of membrane potential was observed shortly after addition of
MiliA in PC-12 and N2a. (b) ROS production in both cell lines, as
shown by immunofluorescence analysis of DCF. (c) Production of
ROS quantitatively measured by DCF fluorescence in a multiplate
reader. Data shown were calculated from three independent exper-
iments and normalised to untreated cells. (d) N2a cells treated with
40 lMMiliA overnight underwent apoptosis and were not rescued by
addition of NAC (15 mM)
Fig. 5 Activation of the ARE, AP-1 and NF-jB transcription factors
after addition of 40 lM MiliA in both cell lines as revealed by
EMSA. DNA-binding activity of NF-jB was completely abolished by
addition of 15 mM NAC. (a) Increased transient binding to the ARE
consensus sequence was observed as early as 1 h post-treatment that
declined thereafter. There was no obvious difference in ARE DNA-
binding activity between PC-12 and N2a cells. (b) AP-1 and (c) NF-
jB were transiently activated in N2a cells peaking at around 2 h post-
treatment. PC-12 cells on the other hand showed more persistant
DNA-binding activities that began 24 h after start of treatment.(d)
Addition of 15 mM NAC completely inhibited MiliA-dependent NF-
jB DNA-binding activity in both cell lines
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AIF appears to play a dual role: it protects cells against
oxidative damage when located in the mitochondria, but
increases the chance to succumb to cell death in response to
severe stress and subsequent translocation of AIF. As there
was a distinct release and nuclear translocation of AIF in
both cell lines after addition of 40 lM MiliA, we analysed
the expression of p53. N2a cells showed a high basal
expression of p53 compared to PC-12 cells and a higher
expression of AIF (Fig. 6a). Treatment of PC-12 with
MiliA lead to up-regulation of p53, which was almost
exclusively localised in the nucleus, whereas N2a cells
showed a down-regulation 24 h post-treatment (Fig. 6b, c).
The stabilisation of p53 in PC-12 cells was unexpected,
since concommittant activation of PKB occurred (Fig. 1c).
PKB has been reported to negatively regulate p53 through
Mdm2 [17]. We, however, found that phosphorylation of
PKB positively regulated p53, as co-treatment with
LY294.002, a PI3-K-inhibitor, efficiently blocked PKB
phosphorylation and stabilisation of p53 (Fig. 6b). A sim-
ilar finding was previously published for p53 activation by
cisplatin that was equally blocked by the PI3-K-inhibitor
[39]. LY294.002, however, did not interfere with the
MiliA-dependent down-regulation but led to a slightly
diminished expression of basal p53 in untreated N2a cells
after incubation with LY294.002 for 1 day (Fig. 6b).
As we had suggested that high p53 expression in N2a
cells might be responsible for the sensitisation towards
apoptosis induced by MiliA, it was surprising to find p53
down-regulation after 24 h in N2a. However, this down-
regulation only occurred after induction of apoptosis. A
time course experiment of p53 expression did neither show
up- nor down-regulation within 4 h post-treatment (Fig. 6
d). To analyse activation of p53, we used an antibody
directed against the phosphorylated form of p53 (Ser15),
which was shown to be essential for its pro-apoptotic
activity [40, 41]. We, however, only found a significant
increase 4 h after addition of 40 lM MiliA, essentially
before AIF translocation was observed (Figs. 6e and 2e). In
PC-12 cells, stabilisation and activation by phosphorylation
of p53 was not observed before 24 h post-treatment, but
well before translocation of AIF could be detected
(Figs. 6e and 3c).
To check if activation of p53 was indeed responsible for
release of AIF and its nuclear translocation, we added
MiliA to cells pre-treated for 30 min with PFTa, a known
inhibitor of p53-transcriptional activity [42]. Consequently,
localisation of AIF remained unchanged in PFTa pre-
treated cells upon administration of MiliA in both cell
types after 6 h (N2a; Fig. 7a) and 3 days (PC-12; Fig. 7c),
respectively. Further, we checked if induction of apoptosis
could be blocked by pre-treatment with PFTa and/or PFTa/
zVAD combined treatment, which in fact was the case:
PFTa alone or in combination with zVAD efficiently
blocked initiation of apoptosis as measured by FACS of
Annexin V/PI-double stained cells in both N2a (Fig. 7b)
and PC-12 cells (Fig. 7d). zVAD (20 lM) alone, however,
Fig. 6 N2a showed higher expression of p53 and AIF compared to
PC-12 cells, and stabilisation of p53 was positively regulated by PI3-
K. (a) Protein levels of p53 and AIF were higher in N2a than in PC-12
cells. (b) Co-treatment with 50 lM LY294.002 efficiently inhibited
MiliA-dependent stabilisation (40 lM, 24 h) of p53 in PC-12 but did
not block down-regulation in N2a cells. It did, however, slightly
diminish basal expression of p53 in N2a cells. (c) p53 was almost
exclusively localised in the nucleus of PC-12 cells before and after
treatment with MiliA for 24 h (40 lM). (d) MiliA-dependent down-
regulation of p53 in N2a cells did not take place before 4 h post-
treatment. (e) Phosphorylation of p53 at Ser15 in response to
treatment with MiliA (40 lM)
Apoptosis (2008) 13:364–376 371
123
-62-
only showed marginal reduction of Annexin V-positive
cells in N2a and no reduction in PC-12. This is in agree-
ment with the finding that PC-12 showed no caspase-
activation in our assays in response to MiliA (Fig. 3b).
Even application of up to 100 lM zVAD did not block
onset of programmed cell death in neither cell line (not
shown).
As LY294.002 blocked stabilisation of p53, we tested if
treatment with the inhibitor 30 min prior to addition of
MiliA would reduce the extent of cell death in N2a.
Co-treatment with LY294.002 efficiently inhibited binding
of Annexin-V after 3 h, and only a fraction of the cells lost
their shape and adherence after 24 h (Fig. 8a, b).
As treatment with LY294.002 slightly reduced basal
levels of p53 in N2a cells (Fig. 6b), we investigated whether
phosphorylation at Ser15 of p53 would be repressed as well.
Use of an antibody directed against P-p53 in immunofluo-
rescence microscopy showed that activation of p53 by
40 lM MiliA was indeed affected by pre-treatment
with LY294.002 (Fig. 8c). 95.5 ± 4.1% of MiliA-treated
cells showed phosphorylation of p53 in immunofluores-
cence microscopy vs. 55.2 ± 4.2% in MiliA/LY294.002
co-treated cells (data calculated from three independent
experiments). This reduction was confirmed by analysis of
protein samples by SDS-PAGE (Fig. 8d) and was obviously
sufficient to prevent immediate onset of apoptosis. However,
MiliA-treated N2a cells in presence of LY294.002 suc-
cumbed to cell death between 24 and 48 h post-treatment
(not shown).
Given that pre-treatment with LY294.002 prolonged
survival of MiliA-treated N2a cells, we also applied the
PI3-K-inhibitor to PC-12 cells to see if neurite extension
and/or late apoptosis would be inhibited. However, PC-12
cells died within 24 h after addition of 50 lM LY294.002
in presence, but also in absence of 40 lM MiliA (not
shown). Therefore we continued with N2a cells and
observed postponed MiliA-dependent activation of the AP-
1 transcription factor in presence of LY294.002 24 h after
start of treatment. Interestingly, DNA-binding activity of
AP-1 was not detected in MiliA-only treated cells at this
time point (Figs. 9a and 5b). MiliA-dependent NF-jB
DNA-binding activity on the other hand remained
unchanged in presence or absence of LY294.002 (Fig. 5c
and not shown). We therefore tested the hypothesis, that
raised AP-1 DNA-binding activity is a pro-apoptotic event
in this context [43]. As binding of c-jun to AP-1 consensus
sequences is considered to be pro-apoptotic [26], we per-
formed supershift analysis using a specific antibody
directed against c-jun. We found c-jun-binding in both in
MiliA-treated N2a after 4 h as well as in PC-12 after 24 h
(Fig. 9b). In addition, the same supershift was also
observed in N2a cells co-treated with LY294.002 and
MiliA after 24 h (not shown).
Discussion
In this study we present evidence that a simple molecule by
activating identical pathways is able to trigger events as
diverse as neurite extension and apoptosis.
Differentiation is a complex process and involves
diverse signalling pathways. In PC-12 cells, neuronal dif-
ferentiation is usually initiated by the binding of NGF to
TrkA and involves the subsequent activation of PI3-K/
PKB, PKCs, Ras and MEK/ERK [5]. MiliA, a pyridone
alkaloid from Paecilomyces militaris [36] basically does
the same: it activates PKB and ERK1/2 [3] but circumvents
the need for TrkA. This results in neurite extension in PC-
12, and apoptosis in N2a cells. The outcome is similar to
that reported for geldanamycin, an Hsp90 inhibitor, which
provoked programmed cell death in PC-12 and neurite
extension in N2a cells [44]. In another study using a MiliA-
related compound, (+)-N-Deoxymilitarinone A, cytotoxic
effects were observed in the human neuroblastoma cell line
IMR-32, and neurite extension in PC-12 cells [45].
We report that MiliA is capable of initially driving two
basically independent signalling pathways. First, it pro-
vides NGF-like activity, leading to neurite extension. The
mechanism for activation of PI3-K/PKB and MEK/ERK1/
2, however, remains elusive. As MiliA showed high
affinity for membraneous compartments, we investigated
possible stimulation of the small G-proteins Ras and Rac
which are activated at the cytoplasmic side of the cellular
membrane [9, 46, 47] but could not detect any consisting
and specific activation neither at early nor late time points
(data not shown).
By additional insertion into mitochondrial membranes,
MiliA disturbed their integrity, which resulted in loss of
membrane potential, release and accumulation of ROS, in
both cell lines at comparable speed. Since addition of NAC
blocked increase of ROS in PC-12 and N2a, but not the
apoptotic pace, we assume that the release of oxidative
molecules from mitochondria did not trigger apoptosis by
itself. Furthermore, NAC did not inhibit cellular death in
N2a and blocked NF-jB-activation suggested that accu-
mulation of ROS was involved in defence and survival
mechanisms. The subsequent release of AIF and its trans-
location to the nucleus was fast in N2a but delayed in PC-
12, and suggests involvement of additional elements that
control release of molecules at mitochondrial level [48].
This was corroborated by the fact that we were unable to
detect co-release of cytochrome C. How exactly MiliA
induces loss of membrane potential, a necessary pre-req-
uisite for subsequent release of AIF [37], needs further
investigation.
Second, it activates p53-dependent apoptosis [19, 20]
mainly through a caspase-independent mechanism involv-
ing nuclear translocation of AIF, a molecule that is
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positively regulated by basal levels of p53 [16]. N2a
showed higher basal levels of p53 and AIF and underwent
apoptosis within a few hours whereas PC-12 had a low
p53-expression and first reacted with up-regulation of
protein-levels before execution of programmed cell death.
In the course of MiliA-induced signalling we found addi-
tional phosphorylation of p53 at Ser15, which is essential
for its pro-apoptotic function [40, 41]. Using PFTa, a
compound that does not inhibit p53 phosphorylation but its
transcriptional activity, abolished MiliA-dependent AIF
translocation and initiation of apoptosis. This suggests that
p53 was involved in regulation of AIF-expression and
localisation.
However, these pathways described are not independent
but interact with each other. Whereas inhibition of ERK1/
2-signalling by the MEK-inhibitor UO126 had not specific
effect (data not shown), blocking of the PI3-K/PKB path-
way by LY294.002 suppressed MiliA-dependent early
execution of apoptosis in N2a cells. This finding is in
contrast to reports showing that inhibition of PI3-K would
lead to stabilisation of p53 and facilitated induction of
apoptosis [17, 49]: rather on the contrary, basal expression
as well as phosphorylation at Ser15 were moderately
repressed. It is, however, in agreement with reports that
showed inhibition of cisplatin-induced, p53-dependent
apoptosis by LY294.002 [39]. Although the PI3-K/PKB-
pathway is mainly known for its pro-survival activity [50],
it contributes in this complex context to apoptosis-induc-
tion. Additionally, it postponed MiliA-dependent AP-1
DNA-binding activity.
A differentiated phenotype in N2a cells could not be
observed, which is likely due to the inhibition of PKB-
derived signalling. Unfortunately, this assumption could
not be verified in PC-12 cells as they fatally reacted to
PI3-K-inhibition as described.
It seems clear that the two cell-lines undergo apoptosis
through the same mechanisms once they are activated to a
similar extent. Further, it seems to be clear that MiliA-
dependent ROS-production does not play a decisive role as
Fig. 8 Inhibition of PI3-K by LY294.002 blocks immediate onset
of apoptosis in N2a cells and partly phosphorylation of p53 at
Ser15. (a) Co-treatment with 40 lM MiliA (3 h) and 50 lM
LY294.002 led to clearly reduced surface binding of Annexin V
compared to the vehicle-treated controls. (b) LY294.002 efficiently
inhibited late onset of cell death in N2a induced by 40 lM MiliA.
(c, d) There was incomplete but significant reduction in p53
phosphorylation in LY294.002 and MiliA co-treated N2a cells after
4 h as shown by immunofluorescence microscopy (c) and SDS-
PAGE (d)
Fig. 7 MiliA-dependent Apoptosis and nuclear translocation of AIF
is blocked by PFTa, an inhibitor of p53 transcriptional activity.
50 lM PFTa, 20 lM zVAD or PFTa and 20 lM zVAD were added
30 min prior to the administration of 40 lM MiliA. (a, c) N2a and
PC-12 cells were incubated with 50 lM PFTa prior to addition of
40 lM MiliA or vehicle only for 6 h (N2a) and 3 days (PC-12),
respectively. The cells were subsequently fixed, stained and analysed
for AIF localisation (green) by immunofluorescence microscopy. The
DNA was counterstained using Dapi (shown in blue). (b, d) FACS
analysis of Annexin V/PI double stained cells revealed a clear
reduction of Annexin V- and Annexin V/PI-positive N2a (b) or PC-12
(d) cells when co-treated with PFTa or PFTa/zVAD plus MiliA for
one (N2a) and 3 days (PC-12), respectively. Addition of zVAD alone
prior to MiliA-treatment only resulted in a minor reduction of
Annexin V-positive cells
b
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both showed almost identical ROS-up-regulation. We
nevertheless assume that it was involved to a certain
degree. ROS also act as secondary messengers in intra-
cellular signal transduction and help to induce or maintain
the oncogenic phenotype of cancer cells [51]. Treatment
with MiliA may just have driven the delicate balance over
the edge. Preliminary data suggest that MiliA-treated pri-
mary cells (bovine lymph node cells and murine bone
marrow mast cells) did not undergo cellular death even
after a week’s incubation. All cancer or cancerous cell lines
tested on the other hand (PC-12, N2a, IMR-32, Jurkat
T-cells, Theileria parva-infected T-cells [52]) died
between 8 and 72 h after start of treatment (P. Ku¨enzi and
M. Hamburger, unpublished results).
Conclusion
Militarinone A induces neurite extension in PC-12 cells by
persistent activation of pathways that are also involved in
NGF-mediated differentiation, namely the PI3-K/PKB and
MEK/ERK pathways. The continuous activation of these
pathways finally leads to up-regulation of p53, release of
AIF from mitochondria, and activation of the c-Jun/AP-1
transcription factor that has also been described as a ‘‘killer
on the transcriptional leash’’ [43]. Application of MiliA to
N2a cells, however, resulted in rapid onset of apoptosis by
nuclear translocation of AIF, activation of caspases and
c-Jun/AP-1. The main difference between the two cell
types was the basal expression of p53, being high in N2a
and low in PC-12. MiliA induced further stabilisation and
activation of p53 as well as p53-dependent release and
nuclear translocation of AIF in PC-12, which eventually
resulted in apoptosis. MiliA induced the self-same path-
ways in both cell lines, initially leading to diverse, but
finally to identical results.
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 Abstract 
 
(E,Z)-3-(3’,5’-dimethoxy-4’-hydroxy-benzylidene)-2-indolinone (indolinone) is an 
alkaloid that has been identified as a pharmacologically active compound in extracts 
of the traditional anti-inflammatory herb Isatis tinctoria. Indolinone has been shown to 
inhibit compound 48/80-induced mast cell degranulation in vitro. We further studied 
the effects of indolinone on some of the signal transduction molecules that are 
responsible for degranulation. Stimulation of mast cells with adenosine resulted in 
phosphorylation of PKB, MEK, MAPK, and PKC. Pre-treatment with indolinone 
inhibited phosphorylation of PKB, MEK and MAPK but phosphorylation of PKC 
remained unaffected. Adenosine-induced production of the lipid second messenger 
phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) was blocked after pre-
treatment with indolinone, and an analysis of kinase activity revealed inhibition of all 
class I PI3-K. Fluorescence microscopy showed that indolinone was equally 
distributed in the cytoplasm and that cellular uptake was terminated within minutes. 
These findings suggest that indolinone acts via inhibition of PI3-K, abolishing 
subsequent intracellular signalling events and ultimately blocking mast cell 
degranulation. 
 
 
 
 
 
Abbreviations: BMMC, murine bone marrow derived mast cells; DNP, dinitrophenyl; 
MAPK, mitogen-activated protein kinase; MEK, MAP kinase kinase; PI3-K, 
phosphatidylinositol 3-kinase; PLC, phospholipase C; PKC, protein kinase C; 
PtdIns(3,4,5)P3, phosphatidylinositol 3,4,5-trisphophate;  
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 Introduction 
 
Isatis tinctoria (woad) is an ancient European dye and medicinal plant. It has 
traditionally been used as a source of indigo for blue dye and as anti-inflammatory 
medicine [1]. In China, the closely related Isatis indigotica is monographed in the 
Chinese Pharmacopoeia where it is indicated as a treatment for inflammation. 
Natural indigo, obtained by processing of various indigo plants, is used in traditional 
Chinese medicine to treat inflamed skin, intestines or mucosa [2]. The anti-
inflammatory and anti-allergic potential of lipophilic Isatis tinctoria leaf extracts was 
confirmed some years ago in a pharmacological profiling involving some 20 clinically 
relevant targets [1,3], and later in several in vivo models for inflammation and allergy, 
and in a clinical pilot study for topical application [4-6].  
Several pharmacologically active constituents of woad have been identified, such as 
tryptanthrin, indirubin, α-linoleic acid, and (E,Z)-3-(3’,5’-dimethoxy-4’-hydroxy-
benzylidene)-2-indolinone (indolinone). Tryptanthrin is a potent inhibitor of COX-2 [7] 
and 5-LOX [8], and of nitric oxide (NO) production catalyzed by inducible NO 
synthase (iNOS) [9]. Indirubin is used in Chinese medicine as an antileukemia 
medicine and has been shown to inhibit cyclin-dependent-kinase 2 (CDK2) [10]. The 
lipid constituent α-linolenic acid inhibited 5-LOX [8] and seems to act as a competitor 
of arachidonic acid and thus reduces the inflammatory response of the cells [11]. 
Indolinone (Fig. 1) inhibited compound 48/80-induced histamine release from rat 
peritoneal mast cells [12].  
 
Fig. 1 - Chemical Structure of indolinone. Structure of (E,Z)-3-(3’,5’-dimethoxy-4’-hydroxy-
benzylidene)-2-indolinone (indolinone). 
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 Indolinone derivatives have been tested in disease models for multiple sclerosis [13], 
cancer [14], HIV [15], and infection [16], and an indolinone derivative, sunitinib, was 
recently approved as tyrosine kinase inhibitor for treatment of renal cell carcinoma 
and imatinib-resistant gastrointestinal stromal tumours [17]. The indolin-2-one 
scaffold seems to exhibit some general kinase inhibitor activity. Substituted indolin-2-
ones occupy the ATP-binding site and act as ATP-mimetic inhibitors [18]. This 
suggested that the effects of indolinone could be due to kinase-inhibitory properties.  
Although many cells are involved in allergy and inflammation, mast cells play an 
important role as initial effectors due to their localisation in the tissue. By release of 
pro-inflammatory molecules, mast cells initialise processes that result in early and 
late phase allergic reactions [19]. They are implicated in many diseases, such as 
allergy and asthma, gastrointestinal disorders, rheumatic diseases and multiple 
sclerosis [20,21]. Degranulation of mast cells requires binding of IgE antibodies to the 
high affinity IgE receptor (FcεRI) for activation and crosslinking of these antibodies by 
subsequent binding of an antigen. The crosslinking induces intracellular signalling 
events that lead to activation of the protein kinase Lyn that in turn phosphorylates 
immunoreceptor tyrosine-based activation motifs (ITAMs) and Syk kinases. Class IA 
PI3-K recognise phosphorylated ITAMs as docking sites, which leads to the 
production of PtdIns(3,4,5)P3 that recruits PKB (also known as Akt), leading to its 
activation and initiates a signalling cascade involving Bruton’s tyrosine kinase (Btk) 
and Phospholipase Cγ and the Raf-MEK-MAPK pathway. This eventually induces 
opening of plasma membrane calcium channels leading to degranulation [22]. 
However, the FcεRI-mediated mast cell response is limited by subsequent de-
phosphorylation of PtdIns(3,4,5)P3 to PtdIns(3,4)P2 by SH2-containing inositol 5’-
phosphatase (SHIP). To circumvent the control of SHIP, murine mast cell responses 
are intensified in vitro and in vivo by autocrine signals depending on functional class 
IB PI3-K such as adenosine, acting through the A3 adenosine receptor (A3AR) [23, 
24, 25, 26]. The stimulation of A3AR exclusively activates PI3-Kγ that transiently 
increases levels of the lipid second messenger PtdIns(3,4,5)P3, resulting in signal-
amplification following FcεRI activation, which was absolutely necessary to sustain 
calcium influx and degranulation [27,28].  
Mast cell stabilisers such as disodium cromoglycate inhibit degranulation and late 
phase allergic reactions [19]. Other anti-inflammatory, anti-allergic or 
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 immunosuppressive drugs such as corticosteroids or calcineurin-antagonists inhibit 
degranulation as well but additionally have many other effects [29]. 
The aim of this study was to elucidate whether indolinone interacts with the pathways 
that lead to mast cell activation and degranulation and at what level this interaction 
occurs.  
 
 
Methods 
Chemicals and Cell Culture 
Murine bone marrow derived mast cells (BMMC) were cultured in Iscove’s modified 
Dulbecco’s medium (IMDM; Sigma- Aldrich, Buchs, Switzerland) supplemented with 
10% heat-inactivated fetal calf serum (FCS; Amimed, Basel, Switzerland), 100 U/ml 
penicillin/streptomycin, and 2 mM L-glutamine (both from Invitrogen, Basel, 
Switzerland). Cells were grown in humified atmosphere containing 5% CO2 and 
maintained with 2 ng/ml recombinant murine interleukin-3 (IL3; PeproTech EC Ltd, 
London, UK). Chemicals used were: stem cell factor (SCF; Biosource, Invitrogen, 
Basel, Switzerland), adenosine (Ade; Sigma-Aldrich, Buchs, Switzerland), LY294002 
(Alexis Corporation, Lausen, Switzerland), and wortmannin (Wort; Sigma-Aldrich). All 
solvents used were from Scharlau (Barcelona, Spain). 
Indolinone was synthesised according to the procedure of Sun et al. [18]. The ratio of 
slowly interconverting E and Z isomers was determined as 81:19 by HPLC [12]. 
Indolinone showed fluorescence when excited at 488 nm or 405 nm, with an 
emission maximum at 499 nm. The absorption maxima are at 256 and 380 nm. 
 
Western Blot 
Immunoblot analysis was performed according to standard procedures. Equal 
amounts of cellular protein were separated on SDS-PAGE and transferred to a 
nitrocellulose membrane. Membranes were blocked and incubated overnight at 4°C 
with specific primary antibody diluted in blocking buffer (5% milk powder in TBS-
Tween): anti-phospho-PKB (Thr308) 1:1000; anti-phospho-MAPK1/2 
(Thr202/Tyr204) 1:1000; anti-phospho-MEK1/2 (Ser 217/221) 1:1000, anti-phospho-
PKC (pan, γ Thr514; all Cell Signaling Technology, Beverly, MA); goat polyclonal 
anti-Actin 1:4000 (Santa Cruz Biotechnology, Santa Cruz, CA). Specific bands were 
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 tagged with HRP conjugated secondary antibodies (Cell Signaling Technology, 
Beverly, MA) and detected using enhanced chemiluminescence (ECL Plus System, 
GE Healthcare, Little Chalfont, UK).  
 
Flow Cytometry 
Analysis of degranulation was performed with annexin V staining of mast cells 
[30,31]. Mast cells were sensitised with anti-DNP-IgE (Santa Cruz Biotechnology, 
Santan Cruz, CA) overnight and incubated with adenosine and DNP-albumin (Sigma-
Aldrich, Buchs, Switzerland) for 20 min. Then, annexin V-Cy5 (Abcam, Cambridge, 
UK) was diluted according to the manufacturer’s protocol and the cells were 
incubated for 10 min. Fluorescence was measured in FL4 (excitation 635 nm, 
emission 680/30 nm). 
Measurement of intracellular indolinone was conducted in the violet 2 channel (FL7) 
(excitation 405 nm, emission 450/50 nm). Cells were analysed directly from medium 
that was diluted with PBS and indolinone (50 µM) was added during data acquisition. 
FACS analysis was performed on a Dako CyAn ADP LX 7 running Summit software 
(DakoCytomation, Glostrup, Denmark). 
 
Fluorescence Microscopy 
BMMC cells were suspended in PBS and left to adhere to glass coverslips and fixed 
in 4% formaldehyde in PBS for a minimum of 15 min at 4 °C. Nuclei were stained 
with DRAQ5 (Alexis Corporation, Lausen, Switzerland) according to the 
manufacturer’s protocol. Cells plated on coverslips were mounted on glass slides 
with Fluorescent Mounting Medium (DakoCytomation, Glostrup, Denmark) and 
visualised by confocal microscopy (Leica DM RXE scanning confocal microscope) 
using Leica confocal software, version 2.5 (Leica Microsystems, Heidelberg, 
Germany). 
 
Phosphatidylinositol (3,4,5)-trisphosphate levels 
Levels of intracellular phosphatidylinositides were determined essentially as 
described [28,32]. Briefly, 4 million cells were incubated with 500 µCi [32Pi] for 60 min 
at 37°C. After removal of non-incorporated [32Pi], cells were treated with inhibitor for 
30 min at 37°C and stimulated with adenosine for 30 s. The reaction was stopped by 
addition of 3 ml methanol/ chloroform (2:1, v/v, with 3 mM BHT and 100 µM NaF). 
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 Phospholipids were extracted with 2.1 ml HCl 2.4 M and 2.1 ml chloroform and the 
organic phase was transferred to a tube with 1 ml methanol/ 0.5 M HCl and extracted 
again. The lower phase was evaporated by nitrogen stream and transferred to 
deacylation. Dried samples were incubated with methylamine solution in water/ 
methanol/ butanol (43: 46: 11) at 53° C for 50 min, all solvent was evaporated under 
vacuum, and then extracted with a mixture of butanol/ light petroleum/ ethyl formiate 
(20:4:1) and water [33]. The water-phase was dried in vacuum and analysed by 
HPLC analysis on a Partisphere SAX (10 µm, 4.6 mm x 250 mm; Alltech, Deerfield, 
IL) column. A gradient of water and 1M NH4H2PO4, pH 3.8 was developed as 
described in [28]. Eluents from the column were examined online with a FLO-ONE 
A500 β-detector (Packard, Perkin Elmer, Monza, Italy).  
 
Kinase assay 
Appropriate concentrations of PI3-K isoforms p110 α, β, γ GST, γ tr, and δ (fused to 
interSH2 domains, a kind gift from Novartis, Basel, Switzerland) were mixed with 10 
µg/ml L-α-phosphatidylinositol (Sigma-Aldrich, Buchs, Switzerland) dissolved in 0.3% 
octylglucoside kinase buffer (10 mM Tris HCl, 3 mM MgCl2, 50 mM NaCl, 0.8 mM 
CHAPS, 1 mM DTT). After 5 min pre-treatment with indolinone or DMSO, 2 µM ATP 
(Roche, Basel, Switzerland) dissolved in kinase buffer were added to start the 
reaction. Reactions were incubated for 30-90 min, depending on the kinase isoform. 
Kinase Glo (Promega, Madison, WI) was added to each well to start the luciferase 
reaction. After 15 min incubation at room temperature, plates (white 96 well 
luciferase plates (Berthold, Bad Wildbad, Germany) were read out in a luminometer 
(Centro LB 960, Berthold) with an integration time of 0.5 s. Samples were run in 
duplicate.  
 
 
Results 
Inhibition of degranulation in murine bone marrow derived mast cells 
Indolinone had been previously shown to inhibit compound 48/80-induced histamine 
release in rat peritoneal mast cells [12]. We reconfirmed this effect in antigen-
stimulated degranulation of murine bone marrow derived mast cells (BMMC), to 
demonstrate that this effect was neither species-dependent nor assay-specific. 
-75-
 BMMC were sensitised overnight with anti DNP-IgE (100 ng/ml) and indolinone (50 
µM) was added 30 min before stimulation where applicable. Degranulation was 
simultaneously induced with the antigen DNP-albumin (5 ng/ml) and adenosine (2 
µM), as stimulation with antigen DNP-albumin alone only resulted in week responses. 
Indolinone pre-treatment reduced the number of degranulated cells from 63.1% ± 
8.7% to 23.5% ± 4.6%, only just above Ctrl level (15.0% ± 0.1%) (Fig. 2A & B). Even 
though we used a different assay setup, another kind of cells, and changed the type 
of degranulation-inducing agents, indolinone clearly inhibited degranulation in 
BMMC. Due to interference with indolinone fluorescence occurring at all wavelengths 
when excited with 488 or 405 nm, typical hexosaminidase-release measurement had 
to be abandoned. Instead, degranulation was measured using Cy5-conjugated 
annexin V. Annexin V-Cy5 was exited at 635 nm and emission was measured at 
680/30 nm. 
 
Fig. 2 - Degranulation of BMMC. (A) Mast cells were sensitised with IgE antibodies over night and 
subsequently challenged with antigen (Ag) and 5 µM adenosine. Indolinone (50 µM) was added to the 
cells 30 min before challenge. Cells were stained with annexin V-Cy5 and degranulation was 
measured by flow cytometry. Shown is a typical experiment. Region R was determined as approx. 
15% degranulation of control cells. (B) Histogram of cells in Region R of three independent 
experiments. Shown are the mean ± S.E.: Ctrl: 15.0% ± 0.1%; Ag + Ade: 63.1% ± 8.7%; Ind + Ag + 
Ade: 23.5% ± 4.6%. 
 
Reduced phosphorylation of selected signal transduction molecules involved 
in degranulation  
Signals that lead to degranulation involve phosphorylation of several signalling 
proteins such as PKB, MEK and MAPK. Furthermore, involvement of PKC has been 
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 suggested [34-36]. Therefore, we checked for phosphorylation of these proteins upon 
stimulation with adenosine and analysed for differences between cells pre-treated 
with indolinone or untreated controls. Stimulation of BMMC with 5 µM adenosine for 
30 s resulted in phosphorylation of PKB (Thr308), MEK1/2 (Ser 217/221), MAPK1/2 
(Thr202/Tyr204), and PKC (pan, γ Thr514). Pre-treatment with 50 µM indolinone 30 
min prior to stimulation diminished the phosphorylation of PKB, MEK, and MAPK, 
whereas phosphorylation of PKC was not affected (Fig. 3A). Pre-treatment with the 
PI3-K inhibitor wortmannin also blocked phosphorylation of PKB, MEK, and MAPK. 
Quantitative analysis by flow cytometry of adenosine-induced PKB phosphorylation 
showed a dose-dependent inhibition after indolinone pre-treatment. Phosphorylation 
of PKB was almost completely blocked by 50 µM indolinone in respect to LY pre-
treatment, and partially by 25 µM indolinone (Fig. 3B). 
 
Fig. 3 - Phosphorylation of important signalling molecules involved in degranulation, analyzed by 
western blot and flow cytometry. (A) Equal amounts of cellular protein were separated by SDS-PAGE, 
transferred to nitrocellulose membrane, and probed using specific antibodies. α-tubulin was used as 
an internal loading control. BMMC cells (0.5 x 106) were starved in 2% serum for 4 h, treated with 
indolinone or inhibitor (Wort) for 30 min, and then stimulated with adenosine (Ade) for 30 s. Untreated 
cells were used as control. Shown are typical results from at least three independent experiments. (B) 
Flow cytometry analysis of PKB-phosphorylation. Cells were fixed and stained using specific 
antibodies, followed by flow cytometry analysis of 10’000 cells per sample in the FITC channel (FL1). 
BMMC cells (0.5 x 106) were starved in 2% serum for 4 h, treated with indolinone (25, 50, and 100 µM) 
or LY (50 µM) for 30 min, and then stimulated with adenosine (5 µM) for 30 s. Shown is a typical result 
from at least three independent experiments. 
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 Adenosine-induced rise of PtdIns(3,4,5)P3 levels inhibited by indolinone 
Generation of PtdIns(3,4,5)P3 by PI3-K induces translocation of PKB towards the 
membrane and its binding to PtdIns(3,4,5)P3 via the pleckstrin homology domain 
[37]. Eventually, PDK1 [38] and mTORC2 [39] phosphorylate PKB at Thr308 and 
Ser473, respectively.  
  
Fig. 4 - Analysis of PI(3,4,5)P3 levels in BMMC cells and activity of PI3-K class IA and IB isoforms. (A) 
BMMC cells were labelled with 32Pi, and phospholipids were extracted, deacylated, and separated by 
HPLC. Peaks of interest were integrated and PtdIns(3,4,5)P3 levels expressed in relation to the 
integral of PtdIns(4,5)P2. BMMC cells (4 x 106) were starved in 2% serum for 4 h, treated with 
indolinone or wortmannin for 30 min, and then stimulated with adenosine for 30 s. Shown are the 
mean ± S.E. of three independent experiments. (B) Chromatograms of PtdIns(3,4,5)P3 analysis, 
recorded by flow scintillation from a typical experiment. (C) PI3-Ks were co-incubated with ATP and 
either indolinone in different concentrations or DMSO as a control. Kinase activity was determined as 
consumption of ATP and residual ATP was measured by luciferase reaction. Samples were measured 
as duplicates in three independent experiments. Kinase activity of the control was defined as 100%.  
 
We analysed PtdIns(3,4,5)P3 levels in BMMC to determine whether inhibition of PKB-
phosphorylation by indolinone was due to reduced PtdIns(3,4,5)P3 production. 
Stimulation of BMMC with adenosine results in elevated PtdIns(3,4,5)P3 levels and 
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 preliminary experiments showed that PtdIns(3,4,5)P3 levels reached a maximum 30 s 
post treatment. PtdIns(3,4,5)P3 levels were quantified relative to PtdIns(4,5)P2 that 
was used as internal standard. This ratio increased 15-fold after stimulation with 
adenosine. Pre-treatment with indolinone significantly reduced this increase to less 
than 5-fold, comparable to pre-treatment with wortmannin (Fig. 4A and 4B).  
 
Inhibition of PI3-Ks class IA and IB by indolinone 
The activity of all PI3-Ks class IA and IB isoforms (α, β, γ, δ), responsible for the 
generation of PtdIns(3,4,5)P3, was tested in an in vitro assay after addition of 
different concentrations of indolinone. The γ isoform was tested in two different ways, 
as the complete GST tagged enzyme and as a trunctuated form with 144 amino 
acids less. We expected reduced kinase activity as the reason for the blocked 
increase of PtdIns(3,4,5)P3 levels. Indeed, indolinone inhibited all PI3-K isoforms to 
some extent (Fig. 4C). When incubated with 50 µM indolinone the α and the δ 
isoform were inhibited to less than 50%, whereas the other isoforms still showed 
activities over 60%. Degranulation in BMMC is predominantly induced by PI3-Kγ and 
we expected a clear inhibition by indolinone.  
 
Localisation of indolinone in BMMC 
Due to the fluorescent properties of indolinone itself, we were able to visualise its 
localisation in cells directly and monitor its uptake into the cell by flow cytometry. 
Although we had expected to see some accumulation at the membrane, analysis of 
indolinone-stained cells by confocal microscopy (Fig. 5A) showed equal distribution 
throughout the cytoplasm, and no staining of the nucleus. Administration of 
indolinone during flow cytometry measurement produced an instant increase in 
fluorescence. After less than 3 min no further increase was detected and 
fluorescence persisted for the duration of the measurement (15 min). This showed 
that indolinone was immediately taken up into the cells and retained in the cytosol 
(Fig. 5B and 5C). We further tested if BMMCs would regain their ability to 
degranulate after removal of indolinone and incubation in indolinone-free media for 
two hours, which was not case (Fig. 5D and 5E). 
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Fig. 5 - Appearance and localization of indolinone in BMMCs. Due to the fluorescent properties of 
indolinone itself, it was possible to monitor its appearance and localisation in the cell. (A) BMMC were 
fixed, stained with indolinone and DRAQ5 and mounted for fluorescence microscopy. The upper panel 
illustrates localisation of indolinone in the cell, the lower panel shows DRAQ5 staining of the nucleus. 
(B+C) Flow cytometry analysis of BMMCs. (B) Administration of 50 µM indolinone during ongoing 
measurement. (C) Fluorescence of BMMC before and after addition of 50 µM indolinone (Ind). (D) 
Mast cells were sensitised with IgE antibodies over night and subsequently challenged with antigen 
(Ag) and 5 µM adenosine (Ade). 50 µM Indolinone (Ind) was added to the cells for 30 min. Cells were 
subsequently washed three times and left for 2 hours or analysed immediately. Cells were stained with 
annexin V-Cy5 and degranulation was measured by flow cytometry. Shown is a typical experiment. 
Region R was determined as approx. 15% degranulation of control cells. (E) Histogram of cells in 
Region R of three independent experiments. Shown are the mean ± S.E.: Ind + Ag + Ade: 23.5% ± 
4.6%; Ind + recovery + Ag + Ade: 23.9% ± 3.4%. 
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 Discussion 
The only drugs in clinical use that directly inhibit mast cell degranulation are disodium 
cromoglycate and its derivative nedocromil [19]. Cromoglycate was developed from 
khellin, a furanochromone from the anti-allergic plant Ammi visnaga. It is a mast cell 
stabilising agent that has been shown to block ion-channels. However, cromoglycate 
likely has additional effects and its mode of action is still not very clear [40]. Various 
other agents have been used experimentally to inhibit degranulation [29], but were 
not applicable for clinical use. The most recent approaches include Syk kinase 
inhibitors [41,42] and anti IgE antibodies. One such anti IgE antibody, Omalizumab 
(Xolair), has recently reached the market [43,44]. 
Extracts of Isatis tinctoria have traditionally been used in the treatment of anti-
inflammatory complaints. Previous studies assigned specific facets of the in vitro 
pharmacological spectrum of the extract to specific compounds [7,8] in this complex 
multi-component mixture. In the model of compound 48/80 stimulated mast cell 
degranulation, indolinone was significantly more potent than disodium cromoglycate 
(IC50 of 15 µM (0.0045 µg/ml) vs 1.5 mM). In an earlier study Isatis extract had an 
IC50 of 2.3 µg/ml in this assay [3]. Given that indolinone is a minor constituent in the 
extract (typical concentrations of 0.04%) [45], it is likely that other components of the 
extract contribute to its mast cell stabilising activity. 
Marquardt et al. showed suppressed degranulation of BMMCs after addition of the 
PI3-K inhibitor wortmannin [46]. Kinase activity of all PI3-K class I isoforms was 
inhibited by indolinone. Hence, it can be assumed that degranulation of BMMC was 
impaired due to PI3-K inhibition. All PI3-K-subtypes were blocked by indolinone to 
some extent, but none of them substantially preferred. PI3-K isoforms important for 
mast cell activation are p110γ and δ. Downstream of the high-affinity IgE receptor 
FcεRI is the tyrosine kinase-activated p110δ and downstream of the adenosine 
receptor the GPCR-activated p110γ [47].  
Consequently, phosphorylation of PKB, MEK, and MAPK was blocked due to 
inhibition of the upstream PI3-Ks. Adenosine-dependent activation of PKC, however, 
was reported to be independent of PI3-K activity and mediated through PLC only 
[48,49]. Our findings agree with that model, since adenosine-induced 
phosphorylation of PKC persisted after indolinone pre-treatment. Furthermore, the 
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 intact PKC phosphorylation revealed that indolinone was not an unspecific inhibitor of 
phosphorylation but rather blocked all events downstream of the PI3-K. 
The calculated distribution coefficient (clogD) of indolinone at pH 7 is 2.28, and polar 
surface area (PSA) is 67.8 Å2. These physico-chemical properties explain its rapid 
cellular uptake, its distribution in the cytoplasma, and its ability to persist within and 
retain its inhibitory role.  
Even though the point of action is supposedly localised near or at the cellular 
membrane, equal distribution in the cytoplasm may confer some advantage since the 
inactive proteins are usually located in the cytoplasm and recruited to the membrane 
upon induction.  
In this study we have shown that indolinone blocks antigen-induced mast cell 
degranulation, decreases adenosine-stimulated production of PtdIns(3,4,5)P3, and 
inhibits activity of all PI3-K class I isoforms. The findings corroborate earlier findings 
with the lipophilic Isatis extract and thus contribute to a better understanding of 
molecular modes of action and synergistic effects of its constituents. 
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 Abstract  
Phosphoinositides (PIs) play fundamental roles as signalling molecules in numerous 
cellular processes. Direct analysis of PIs is typically accomplished by metabolic 
labelling with 3H-inositol or inorganic 32P followed by deacylation, ion-exchange 
chromatography, and flow scintillation detection. This analysis is laborious, time 
consuming, and involves massive amounts of radioactivity. To overcome these 
limitations we established a non-radioactive LC-ESI/MS assay for the separation and 
analysis of deacylated PIs that allows discrimination of all isomers without the need 
for radioactive labelling. We applied the method to various cell types to study the PI 
levels upon specific stimulation. 
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 1. Introduction 
Biology of phosphoinositides 
The inositol containing glycerophospholipids, collectively known as phosphoinositides 
(PIs), play a fundamental role in diverse cellular functions such as cell growth and 
differentiation, motility, calcium mobilisation and oncogenesis [1,2]. The family of the 
phosphoinositides consists of the mutual non-phosphorylated precursor 
phosphatidylinositol (PtdIns) and seven members with different phosphorylation 
patterns on the myo-inositol ring, where the 3-, 4-, and 5-positions can be 
phosphorylated by specific kinases (Fig. 1 A).  
 
Fig. 1. A. General structure of all phosphoinositides, numbering of the ring is indicated and shows the 
positions of the phosphorylations. B. Structure of a typical PI, sn-1-stearoyl-2-arachidonyl-
phosphatidylinositol and the performed deacylation step, resulting in cleavage of the lipid moiety. 
 
PtdIns and its phosphorylation products phosphatidylinositol-4-phosphate (PtdIns4P) 
and phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) form the so called 
canonical pathway [3] and are believed to be kept at constant levels at the plasma 
membrane. The other PIs are considered to be low-abundant signalling molecules 
that transiently appear upon stimulation. Stimulation with growth factors or insulin 
leads to increased PtdIns(3,4,5)P3 levels, which in turn produces specific cellular 
responses. The bisphosphorylated PIs, PtdIns(3,4)P2, PtdIns(4,5)P2, and 
PtdIns(3,5)P2 play distinct roles in signal prolongation after PtdIns(3,4,5)P3 inducing 
stimuli, regulation of the actin cytoskeleton and vesicle transport, respectively [4-8]. 
Phosphoinositides monophosphates were long thought to be mere intermediates in 
the pathway but are now recognised to possess specific functions themselves in 
protein sorting, vesicular trafficking and in osmotic stress response [9-12]. 
 
-89-
 Detection of PIs 
Analysis of PIs has been achieved in several ways. Most frequently, metabolic 
radioisotope labelling with inorganic 32P or 3H-inositol, lipid extraction, 
chromatographic separation and radiographic analysis of phosphoinositides is 
performed [13-15]. Metabolic labelling involves very high doses of radioactivity 
(GBq), long labelling times, and only detects the turnover of PIs, whereas dormant 
pools of PIs remain unlabelled. More recent approaches include fluorescent-labelled 
binding proteins for specific PIs, and antibodies directed against PIs [16,17]. 
However, differentiation of all mono- and bisphosphorylated positional isomer PIs, 
has not been achieved yet.  
Two fundamentally different approaches have been pursued in PI detection: (i) a 
comprehensive profiling of intact PIs [18-21], and (ii) head group analysis after 
cleavage of the lipid moieties [22,23]. The first approach used in lipidomics leads to a 
highly complex picture due to a plethora of closely related molecules that only vary in 
their lipid moieties. Separation and detection of the head groups following 
deacylation (Fig. 1 B) is a much more suitable approach if the focus lies on the 
signalling functions of PIs. Nonetheless, analysis of the low abundant PIs remains 
highly challenging. 
As alternatives to radioisotope labelling, analysis by mass spectrometry [24], 
suppressed conductivity detection [25] and evaporative light scattering detection 
(ELSD) [26] have been used. Unfortunately, none of these allowed a discrimination of 
all isomers. An LC-ESI/MS method for separation of deacylated PtdInsP2 isomers on 
a cyclodextrin column has been recently published [14]. However, chromatography 
suffered from poor peak shape and co-elution of PtdIns(3,5)P2 and PtdIns(3,4,5)P3.  
Since all of the PIs can be interconverted by specific kinases and phosphatases, 
inhibition, stimulation, modification, or deletion of one of these enzymes may have 
profound implications on the biological response. Therefore the separation and 
simultaneous quantitative detection of all PIs are of major importance for a better 
understanding of their biological roles. 
We have developed and describe here an LC-ESI/MS method for headgroup 
analysis of all PIs that allows a complete separation of PtdInsP and PtdInsP2 isomers 
using a polar endcapped RP-18 column and a volatile ion-pairing reagent. We also 
show selected applications of our method to PI analysis in relevant cellular models. 
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 2. Experimental 
2.1. LC-MS instrumentation 
HPLC separation was carried out on an Agilent series 1100 system equipped with 
degasser, binary high pressure mixing pump, and column thermostat (Agilent 
Technologies, Waldbronn, Germany). A liquid handler 215 (Gilson, Mettmenstetten, 
Switzerland) was used as autosampler. The HPLC was coupled to an Esquire 3000 
ion trap mass spectrometer equipped with an electrospray (ESI) interface (Bruker 
Daltonics, Bremen, Germany).  
Data acquisition and processing was performed using HyStar 3.0 software from 
Bruker Daltonics.  
 
2.2. LC Method 
2.2.1. Ion-pair chromatography 
N, N-Dimethylhexylamine (DMHA; Acros, Thermo Fisher, Wohlen, Switzerland) was 
used as ion-pair reagent [27]. Mobile phase A consisted of 5 mM DMHA in water 
adjusted to pH 7.0 with acetic acid (Sigma-Aldrich, Buchs, Switzerland) and mobile 
phase B of acetonitrile or methanol with 5 mM DMHA and an equal amount of acetic 
acid. All solvents were from Scharlau (Scharlau, Barcelona, Spain). 
 
2.2.2. Columns 
Various columns were tested for suitability in phosphoinositide analysis, including 
Atlantis C18 (150 x 4.6 mm, 5 µm) and T3 (150 x 3.5 mm, 3 µm; Waters, Baden, 
Switzerland), Nucleosil C100 (250 x 4.6 mm, 5µm; Macherey-Nagel, Düren, 
Germany), LiChrosphere Diol (125 x 4.0 mm, 5 µm; Merck, Darmstadt, Germany) 
and Aqua C18 (250 x 4.6 mm, 5 µm and 75 x 2.0 mm, 3µm; Phenomenex, Torrance, 
CA).  
 
2.2.3. Separation of phosphoinositides 
Method 1  
Separation of deacylated PIs with different numbers of phosphorylations; PtdIns, 
PtdInsP, PtdInsP2, and PtdInsP3, was achieved by ion pair chromatography on a 
modified RP-column (Aqua, Phenomenex C18 125 Å, 75 x 2.0 mm, 3 µm). A gradient 
from mobile phase B (acetonitrile) 0.1% to 50% in 25 min and a wash step (50% B to 
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 100% B in 3 min, 100% B for 12 min, 100% B to 0.1% B in 5 min, 0.1 % B for 5 min) 
was applied. 
Method 2 
Separation of deacylated PIs with different numbers of phosphorylation plus 
additional separation of phosphoinositides bisphosphate isomers PtdIns(4,5)P2, 
PtdIns(3,5)P2, PtdIns(3,4)P2, was achieved by ion pair chromatography on a modified 
RP-column (Aqua, Phenomenex C18 125 Å, 250 x 4.6 mm, 5 µm). A gradient from 
mobile phase B (acetonitrile) 15% to 35% in 40 min followed by a wash sequence 
(35% B to 100% B in 2 min, 100% B for 15 min, 100% B to 15% B in 3 min, 15 % B 
for 5 min) was applied. 
Method 3 
Separation of PtdIns(3)P, PtdIns(4)P, and PtdIns(5)P, additionally to separation of all 
other PIs, was performed with methanol as mobile phase B and a gradient from 15% 
to 50% in 60 min, followed by a wash step (50% B to 100% B in 2 min, 100% B for 15 
min, 100% B to 15% B in 3 min, 15 % B for 5 min). 
 
2.3. Mass spectrometry 
Negative ion LC–MS spectra on the ion trap instrument were recorded after 
optimization of settings, under ion charge control conditions (ICC 20000) at a scan 
speed of 13000 m/z/s, using a gauss filter width of 0.2 m/z. Nitrogen was used as a 
drying gas at a flow rate of 10 L/min and as a nebulizing gas at a pressure of 30 psi. 
The nebulizer temperature was set to 300°C. Spectra were recorded in the range of 
m/z 200–600 in negative mode. Capillary voltage was at 4500V, endplate offset at 
−500V, capillary end voltage at −115.0V, skimmer voltage −40.0V and trap drive at 
53.4. 
 
2.4. Flow scintillation analysis 
Levels of radioactively labelled intracellular phosphatidylinositides were determined 
essentially as described [28]. Briefly, 4 million cells were incubated with 500 µCi 32Pi 
for 60 min at 37°C. After removal of non-incorporated 32Pi, cells were extracted as 
described below. Eluents from the column were splitted and examined online with a 
FLO-ONE A500 β-detector (Packard, Perkin Elmer, Monza, Italy).  
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 2.5. Chemicals and cell culture 
Murine bone marrow cells were cultured in Iscove’s Modified Dulbecco’s medium 
(IMDM; Sigma-Aldrich) supplemented with 10% heat-inactivated fetal calf serum 
(FCS; Amimed, Basel, Switzerland), 100 U/ml penicillin/streptomycin, and 2 mM L-
glutamine (both from Invitrogen, Basel, Switzerland). Cells were grown in humified 
atmosphere containing 5% CO2 and maintained with 2 ng/ml recombinant murine 
interleukin-3 (IL3; PeproTech EC Ltd, London, UK).  
Human embryonic kidney cells HEK 293 were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Sigma-Aldrich) supplemented with 10% FCS, 100 U/ml 
penicillin/streptomycin, and 2 mM L-glutamine. Cells were transfected with jetPEI 
cationic polymer transfection reagent (Polyplus-transfection, Illkirch, France) 
according to the manufacturers instructions. 24 h before transfection, cells were 
plated at 106 cells/ 25 cm2 flask, then transfected with 2.6 µg GST-Vps34 and 0.4 µg 
Myc-S6K. 30 h after transfection, cells were starved over night and experiments were 
performed the following day. 
Platelets were isolated from blood of healthy donors. Blood samples were mixed with 
acid citrate dextrose ACD (10.1 mM glucose, 30µM citric acid, pH 6.5 in 0.9% NaCl, 
all from Sigma-Aldrich) and centrifuged for 5 min at 1000g [29]. Platelet rich plasma 
was collected and washed in PBS. 
Chemicals used for experiments were: Adenosine (Ade), N-Formyl-Met-Leu-Phe 
(fMLP), wortmannin (wort) (all from Sigma-Aldrich).  
Phosphoinositide standards used were: Phosphoinositides sodium salt from bovine 
brain (Sigma-Aldrich), PtdIns(3,4)P2, PtdIns(3,5)P2, and PtdIns(3,4,5)P2 as 1,2-
dioctanoyl-sn-glycero-3-phosphoinositolphosphates ammonium salt and PtdIns3P 
and PtdIns5P as 1-heptadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)- sn-glycero-3-
phosphoinositolphosphates ammonium salt from Avanti Polar Lipids (Avanti Polar 
Lipids, Alabaster, AL). 
 
2.6. Extraction, deacylation, and sample preparation   
Extraction of PIs was adapted from Ogiso [24], a modified acidic Bligh-Dyer 
extraction [30] with addition of NaCl to the aqueous phase, which helps to reduce 
loss of PIs. Briefly, ca. 106 cells were extracted with 2 ml Methanol, 2 ml 1 M HCl, 
0.15 ml 2 M NaCl and 2 ml chloroform (Solvents from Scharlau, other reagents from 
Sigma-Aldrich). Methanol was supplemented with PhosSTOP (Roche, Basel, 
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 Switzerland), 1 mM NaF, 3 mM BHT, and 0.5 mM phosphatidic acid (all Sigma-
Aldrich). The two phases were mixed well and centrifuged shortly for separation. The 
lower organic phase was removed, evaporated by nitrogen stream and transferred to 
deacylation (Fig. 1 B). Dried samples were incubated with methylamine solution in 
water/methanol/n-butanol (43: 46: 11) at 53° C for 50 min, all solvent was evaporated 
under vacuum, and then extracted with a mixture of n-butanol/petrol ether/ethyl 
formiate (20:4:1) and water [31]. The water-phase was dried in vacuum and the 
samples were dissolved in 40 µl of solvent A for LC-MS analysis.  
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 3. Results and discussion 
3.1. Separation of phosphoinositides in order of increasing phosphorylation 
Separation of anionic or phosphorylated compounds is typically achieved by ion-
exchange chromatography. However, typical ion-pairing reagents are not volatile 
and, hence, not compatible with LC-MS. We tested several volatile and MS-
compatible ion-pairing reagents, such as formic acid, ammonium formiate and N,N-
dimethyl-hexylamine (DMHA) and applied them on various columns (Nucleosil C100, 
LiChrospher Diol, and Phenomenex Aqua C18). The only acceptable separation of a 
phosphoinositide reference mixture was achieved on a short (75 mm) Phenomenex 
Aqua column with the addition of DMHA. Subsequently, we tested different gradient 
profiles, column temperatures, pH and concentrations of DMHA to optimize 
separation. Column temperature had a slight impact, and the best separation was 
obtained at 15°C. In contrast, pH of the mobile phase was critical. Best results were 
obtained at pH 7, while lower pH values lead to peak tailing and split peaks and 
higher pH resulted in shorter retention times. Increase of DMHA concentration from 5 
mM to 10 mM and 20 mM did not enhance the quality of the separation. A water-
acetonitrile gradient was applied and the final gradient program was 0.1%-50% ACN 
(containing 5 mM DMHA) in 25 minutes, leading to the separation of a PI standard 
mixture shown in Fig. 2 A. Peaks shown resulted from 0.1 µg of deacylated 
PtdIns(3,4,5)P3 standard mixed with 4 µg of deacylated phosphoinositde extract 
(mixture of PtdIns, PtdIns4P and PtdIns(4,5)P2). 
Separation of a mixture of PIs standards was also achieved under isocratic 
conditions (27% ACN and 73% water (5 mM DMHA)) but separation of biological 
samples, however, could not be achieved under these conditions, probably due to 
interference with the biological matrix.  
To test the applicability of our method to biological samples, we analysed mast cell 
extracts. Mast cells are known to produce large amounts of PtdIns(3,4,5)P3 upon 
activation that can be provoked in vitro by stimulation with adenosine [28]. Murine 
bone marrow derived mast cells (BMMCs) were stimulated with 5 µM adenosine for 
30 sec, the lipids were extracted, deacylated and transferred to LC-MS analysis, 
where phosphoinositides were separated with method 1. Our method clearly 
succeeded in reproducing the increased amounts of PtdIns(3,4,5)P3 upon stimulation 
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 of mast cells with adenosine, whereas peaks of PtdIns and PtdInsP remained 
constant (Fig. 2 B, C).  
 
Fig. 2. A. Extracted ion chromatogram (EIC) of deacylated phosphoinositide standards (PtdIns, 
PtdInsP, PtdInsP2, and PtdInsP3) mixture. B. EIC of cell samples from 4 mio BMMC and standards. 
Cells were stimulated with Adenosine (Ade) 5 µM for 30 s to induce production of PtdInsP3. C. Peaks 
of PtdInsP2 and PtdInsP3 from control cells in relation to stimulated cells, levels of PtdInsP3 increased 
after stimulation with Adenosine. Column: Phenomenex Aqua C18 (75 x 2 mm, 3 µm). Solvent A: 
H2O/5 mM DMHA, Solvent B: Acetonitrile/5mM DMHA. Gradient: 0.1% B to 50% B in 25 min. 
 
3.2. Regioisomer separation of phosphatidylinositol bisphosphates 
To achieve separation of PtdInsP2 regioisomers various columns were tested, 
including Nucleosil C100, Atlantis C18, Atlantis T3, and Phenomenex Aqua C18. The 
separation was only achieved on a 250 mm long Phenomenex Aqua column with 
application of a water-acetonitrile gradient, under addition of 5 mM DMHA as ion-pair 
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 reagent (method 2). A mixture of standards of all PtdInsP2 isomers was separated in 
the elution order of PtdIns(3,4)P2, PtdIns(4,5)P2, and PtdIns(3,5)P2 (Fig. 3 A, B). 
Peaks shown resulted from 0.1 µg of deacylated PtdIns(3,5)P2 and PtdIns(3,4)P2 
standard mixed with 4 µg of deacylated phosphoinositde extract (mixture of PtdIns, 
PtdIns4P and PtdIns(4,5)P2). Several other solvent mixtures and addition of modifiers 
were tested. A gradient of water-methanol (method 3) resulted in separation as well, 
producing a change in elution order to PtdIns(3,4)P2, PtdIns(3,5)P2, and 
PtdIns(4,5)P2 (Fig. 3 C, D).  
 
Fig. 3. A + B. Separation of a standard mixture of PIs containing all PtdInsP2 regioisomers B. Elution 
of the isomers of PtdInsP2 in following order: PtdIns(3,4)P2, PtdIns(4,5)P2, and PtdIns(3,5)P2. Column: 
Phenomenex Aqua C18 (250 x 4.6 mm, 5 µm). A: H2O, 5 mM DMHA, B: Acetonitrile, 5mM DMHA. 
Gradient: 15% B to 35% B in 40 min. C + D. Separation of a standard mixture of PIs containing all 
PtdInsP2 regioisomers D. Separation of PtdInsP2 isomers in sequence of PtdIns(3,4)P2, PtdIns(3,5)P2, 
and PtdIns(4,5)P2. Column: Phenomenex Aqua C18 (250 x 4.6 mm, 5 µm). A: Methanol/5 mM DMHA, 
B: Acetonitrile/5 mM DMHA. Gradient: 15% B to 50% B in 60 min. 
 
As a practical example for the analysis of PtdIns(3,5)P2 in biological samples, we  
selected Vps34 transfected HEK 293 cells under hyperosmolar stress [22,25]. The 
PI3-kinase Vps34 is known to stimulate osmotic stress related production of 
PtdIns(3,5)P2 in yeast [22]. HEK Vps34 were incubated in medium supplemented 
with 1M NaCl solution for 10 minutes inducing stimulation of Vps34 and generation of 
PtdIns3P that lead to production of PtdIns(3,5)P2. As can be seen in Fig. 4 A + B, the 
transfection with Vps34 already induced some production of PtdIns(3,5)P2, which 
was then further increased upon NaCl hyperosmotic stimulation. 
-97-
 Analysis of PtdIns(3,4)P2 in biological samples was performed with human blood 
platelets. In comparison to many other cell models, platelets produce PtdIns(3,4)P2 in 
relatively large amounts upon activation. PtdIns(3,4,5)P3 is degraded to PtdIns(3,4)P2 
by the 5-phosphatase SHIP1 [32]. PtdIns(3,4)P2 is responsible for the persistence of 
the signal induced by PtdIns(3,4,5)P3 [8,33]. For detection of PtdIns(3,4)P2, platelets 
were stimulated with fMLP for 90 s. This resulted in elevated amounts of 
PtdIns(3,4)P2 which were not present in control cells (Fig. 4 C, D).  
 
Fig. 4. Analysis of phosphoinositide cell samples A + B. Extracted ion chromatograms (EIC) of HEK 
Vps34 cell samples showed increased amounts of PtdIns(3,5)P2 , that were further increased by 
stimulation with 1M NaCl for 10 minutes. C + D. EIC of lipids extracted from platelets, control sample 
and stimulated with fMLP for 1 min. Stimulation induced generation of PtdIns(3,4)P2 that was not 
present in the control sample. Column: Phenomenex Aqua C18 (250 x 4.6 mm, 5 µm). A: H2O, 5 mM 
DMHA, B: Acetonitrile, 5mM DMHA. Gradient: 15% B to 35% B in 40 min. 
 
3.3. Regioisomer separation of phosphatidylinositol monophosphates 
Separation of the mono-phosphorylated isomers was only achieved with methanol as 
organic modifier (Fig. 5 A, B), while use of acetonitrile resulted in co-elution of 
PtdIns3P and PtdIns5P. 
We tested the practical applicability of these conditions with Vps34 transfected HEK 
cells. Vps34 is stimulated by amino acid addition through a yet unknown mechanism 
[34]. Starvation and subsequent amino acid supplementation stimulates Vps34 and 
induces the generation of PtdIns3P [35,36]. HEK Vps34 cells were serum and amino 
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 acid starved for 12 h and 2 h, respectively, stimulated for 30 min by addition of serum 
and amino acids, prior to extraction of lipids, deacylation and analysis. The 
stimulation with serum and amino acids induced synthesis of PtdIns3P, which, in 
contrast, was inhibited by incubation with the pan-PI3-kinase inhibitor wortmannin 15 
min prior to and during stimulation with amino acids and serum (Fig. 5 C, D). 
 
Fig. 5. A + B. Extracted ion chromatogram (EIC) and base peak chromatogram (BPC) of mixed 
standards of phosphoinositide monophosphates separated according to method 3. Separation of 
PtdIns3P, PtdIns4P, and PtdIns5P was achieved. C. BPC and EIC of a HEK Vps34 cell sample. D. 
EIC of HEK Vps34 cell samples that were amino acid stimulated and incubated with wortmannin 15 
min prior to and during amino acid stimulation. The increase in PtdIns3P following amino acid 
starvation and subsequent stimulation was blocked by addition of wortmannin. Column: Phenomenex 
Aqua C18 (250 x 4.6 mm, 5 µm). A: Methanol/5 mM DMHA, B: Acetonitrile/5 mM DMHA. Gradient: 
15% B to 50% B in 60 min. 
 
3.4. Comparison with radiolabelling method 
For comparison with the standard detection method of scintillation analysis, we 
applied radiolabelled samples to the newly developed HPLC method combined with 
subsequent scintillation analysis. This also gave a reconfirmation of the peaks 
measured with MS. The large loop size of 1 ml within the flow scintillation analyser 
and a flow rate of only 0.5 ml/min resulted in significant peak broadening and 
asymmetry. Nonetheless, peaks of the major PIs could be detected (Fig. 6 A, B). A 
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 radioactive labelled cell sample, and a labelled standard of PtdIns3P showed all 
major PI peaks at the same retention times as when detected with MS (Fig. 6 C). 
Furthermore it showed a different retention time than the PtdIns4P peak of the cell 
sample.  
 
Fig. 6. A + B. Total ion chromatogram (TIC) and extracted ion chromatogram (EIC) of a HEK Vps34 
control cell sample separated according to method 3. C. Chromatogram of parallel online flow 
scintillation analysis of the same HEK Vps34 cell sample and a standard of PtdIns3P. Column: 
Phenomenex Aqua C18 (250 x 4.6 mm, 5 µm). A: Methanol/5 mM DMHA, B: Acetonitrile/5 mM 
DMHA. Gradient: 15% B to 50% B in 60 min. 
 
3.5. Discussion 
The separation of PIs differing in degree of phosphorylation was successfully 
achieved with method 1 and was successfully applied to analysis of 
phosphoinositides in cell samples. The choice of a polar endcapped RP column and 
an appropriate volatile ion-pairing reagent was decisive for good separation and 
highly symmetrical peak shapes. For analysis of PtdIns(3,4,5)P3 this method offers a 
good alternative to currently used HPLC methods using radiolabelling and ion-
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 exchange columns. The short analysis time facilitates handling of large sample 
numbers.  
A satisfactory separation of PtdInsP2 isomers was achieved on the same column 
type. However, maximum column length was needed to obtain the required 
separation performance. This analytical method offers new perspectives for research 
on phosphoinositide-signalling. The low abundant PtdInsP2 isomers can be 
separated with method 2 and analysed without the need for radioactive labelling. 
Furthermore a complete separation of PtdIns3P, PtdIns4P, and PtdIns5P was 
achieved by applying methanol instead of acetonitrile as solvent B (method 3). This 
isomer separation has not been possible before. Also the PtdInsP2 isomers were 
separated with method 3. However, the changed elution order as compared to 
method 2 precludes a complete separation of the highly abundant PtdIns(4,5)P2 from 
the minor PtdIns(3,5)P2. Therefore, analysis of PtdIns(3,5)P2 should be performed 
with method 2. Depending on the research focus the suitable method can be applied 
and produces better separation of isomers than what was possible before. 
Separation of PtdInsP2 isomers has been shown before on a cyclodextrin column 
[14] but produced co-elution of PtdIns(3,4,5)P3 and PtdIns(3,5)P2. Furthermore 
separation of PtdInsP isomers was neither shown nor discussed in that publication. 
Compared to a cyclodextrin column the polar endcapped RP-column is more robust, 
offers superior separation performance for PIs, and is easier to use with respect to 
predictability of chromatographic behaviour. 
All methods presented here were tested in relevant biological samples. However, the 
extraction procedure of PIs still remains a major concern. As extensively discussed 
by Ogiso et al. [24], recovery rates of PIs are generally poor and decrease with 
increasing phosphorylation. Due to the amphiphilic properties these lipids are difficult 
to extract. The ionic headgroup adsorbs easily to glass surfaces, whereas the lipid 
moiety adsorbs to plastic. Glass surfaces adsorption can be prevented by silanized 
glassware, plastic surfaces can be pretreated with lipids as adsorption protectants. 
We used plastic tubes, lipids as adsorption protectants, phosphatase inhibitors to 
prevent artefactual changes in PI patterns, and were able to significantly increase the 
recovery of analytes. However, further optimization of the extraction protocol will be 
needed in the future to enable a quantitative recovery of deacylated PIs and truly 
quantitative analysis. 
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 Parallel detection with online flow scintillation and mass spectrometry showed the 
comparability of the methods and, at the same time, the significantly better peak 
shape achieved in LC-MS. There are numerous other drawbacks with radiolabelling, 
such as the potential harmfulness of radioisotopes for the user and the environment, 
the short half-life of 32Pi, a need for high doses per experiment, high costs, and 
limited applicability in long-term experiments due to loss of signal and radioactivity-
related degradation of biomolecules.  
The LC-MS methods presented here offer a superior approach for analysis of 
intracellular PI-levels including differentiation of PtdInsP and PtdInsP2 isomers. 
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 C. CONCLUSIONS 
 
 
˝When moving forward towards the discovery of the unknown, 
 the scientist is like a traveller who reaches higher and higher summits  
from which he sees in the distance new countries to explore˝ 
 – Louis Pasteur, Free lance of Science, Chapter III (p.87) 
 
 
 
Isolated natural products that had shown diverse biological activity in previously 
published tests, namely militarinone A and indolinone were analysed for their direct 
effect on molecular signalling processes. Whereas militarinone A had initially shown 
neurotrophic activity in PC12 cells, indolinone pronouncedly blocked degranulation of 
rat peritoneal mast cells. Degranulation is dependent on phosphoinositide signalling. 
This eventually prompted us to have a closer look at phosphoinositide-levels in living 
cells and to develop an improved analysis that offers significant advantages over the 
current approach using radioactive labelling and ion-exchange HPLC. 
 
Published results of militarinone A reporting it as a neurotrophic substance were 
found to describe an intermediate phenomenon restricted to PC12 cells, since other 
cell lines underwent apoptosis within 24h. We propose that this difference is due to 
varying constitutive levels of p53. Hence, increased neuronal outgrowth could not be 
confirmed as a general activity of militarinone A, as this effect was strongly 
dependent on the cell type. Although the exact mechanism of action and the direct 
target of militarinone A could not be determined, the discovery of militarinone A as an 
apoptosis-inducing agent interfering with p53 transcriptional activity may open a new 
area for further studies. Regulation of p53 and the plethora of factors influencing its 
activity are still not fully understood. Of particular interest are preliminary data 
indicating that primary cells (bovine lymph node cells and BMMC) do not undergo 
apoptosis even after incubation for one week with militarinone A, whereas all cancer 
or cancerous cells tested (PC12, N2a, IMR-32, Jurkart T-cells, Theileria parva-
infected T-cells) died within 72 hours at the latest. This suggests that transformed 
cells might be more sensitive to p53-dependent apoptosis, which is supported by the 
fact that p53 is mutated in 50% or more of all cancers known.  
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 The study on militarinone A clearly demonstrates the importance of selecting 
appropriate assays for screening and subsequent bioactivity tests. Once an active 
extract or substance has been identified its activity should be assessed in various 
cells lines of different species to verify the observed effect. Testing of newly identified 
natural products on a subset of defined cells would yield a more comprehensive 
picture of their bioactivity profile that would allow a better comparison of different 
compounds. If all data were fed into a single database, eventually a system biology 
or ‘-omics’ –type activity picture would emerge.  
 
In the study on indolinone, we confirmed the initially observed stabilising effect on 
mast cells of a different species and in a different assay set-up. We showed that 
indolinone efficiently blocked PtdInsP3 production due to inhibition of all class I PI3-
kinases, therefore preventing activation of Akt and subsequent mast cell 
degranulation. The concentrations necessary to obtain the observed effect in vitro, 
however, were too high to consider in vivo testing.  
 
Since mast cell degranulation depends on phosphoinositide signalling we studied 
phosphosinositide levels in living cells upon stimulation. For this purpose, we 
developed a method that allows individual analysis of all phosphoinositides, including 
all PtdInsP- and PtdInsP2-isomers. This novel method based on ion-pair 
chromatographic separation and ESI-MS detection offers substantial perspectives for 
application in phosphoinositide-signalling research as it allows relative quantification 
of all the different PIs in cells.  
Phosphoinositides are upstream members of various important signalling cascades 
such as the Akt-, PKC-, and PLC-pathway and, hence, involved in a multiplicity of 
cellular processes. While the importance of PtdInsP2 and PtdInsP3 in signalling has 
long been recognized, PtdInsP has received little attention only. Our LC-MS method 
facilitates PI analysis and will contribute to the further elucidation of their role in 
cellular signalling.  
 
In contrast to the industrial drug discovery approach, where chemical libraries are 
screened for molecules with activity in a given assay, the strength of natural product 
discovery lies in identification of new mechanisms or drug targets. Assignment of an 
observed effect to a defined molecular interaction is extremely challenging. In the 
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 study on militarinone A we could not determine the specific interaction and 
mechanism, although we have elucidated parameters involved in its activity. 
However, the concept of a step-by-step examination of a signalling pathway 
associated with an observed effect (degranulation) and determination of the point of 
action was successfully applied in the case of indolinone. This strategy could be 
analogously applied for other natural products with preliminary assessed specific 
activity but unknown mechanism of action.  
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